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ABSTRACT
The injury border zone (IBZ), a region of transitional tissue between intact
myocardium and the ischemic area, is often the site of lethal reentrant arrhythmia
generation in post-myocardial infarction (MI) patients. Disruption to normal
connexin43 (Cx43) localization at the intercalated disc (ID), separation of myocytes
by activated fibroblasts and deposited scar tissue are thought to be factors that
render the IBZ a pro-arrhythmic substrate, though there is a current need to better
understand these changes so directed therapies can be developed. There are no
clinically available therapies focused on the mechanistic changes in the IBZ.
Additionally, generation of new compounds is challenged by the inefficiencies of
the drug development pipeline, including the use of in vitro testing platforms that
are of little relevance to human disease. In order to address the need for directed
therapies and improved testing platforms, we developed a 3D in vitro aggregate
model of the IBZ that was validated against a murine cryo-injury model of
infarction. This model was used to examine the changes in heterocellular myocytefibroblast interactions via Cx43 and cell organization patterns in response to αCT1
– a Cx43 carboxyl-terminal mimetic peptide which was previously shown to alter
cell organization in the IBZ of a murine cryo-injury model. Imaging results indicated
that αCT1 increased fibroblast migration, as well as myocyte cohesion, as
evidenced by increased cell clustering in aggregates at 72 hours. This was likely
an effect of Cx43 adhesion properties. Optical mapping studies indicated that
αCT1 could protect cryo-injured hearts against conduction delay through the IBZ
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in conditions of altered extracellular ion concentration. Subsequent analyses from
a gap junction (GJ) intercellular communication (GJIC) assay indicated that this
may be a result of altered communication, as αCT1 was found to decrease GJIC
in myocyte-fibroblast connections and in fibroblast-fibroblast connections. This
decrease in GJIC was correlated with an increase in Cx43 phosphorylated at
serine 368 (pS368) in myocyte-fibroblast interactions in vitro an in vivo, which is
known to decrease GJ channel conductance. Super-resolution imaging of GJ
plaques revealed a novel sub-domain organization with respect to nonphosphorylated Cx43 and Cx43 pS368. Together, the data provided in this
dissertation describe the development of a novel in vitro model of the IBZ of
relevance to drug response and disease mechanism that can be used as a highthroughput testing platform for candidate compounds. These studies, furthermore,
suggest the importance of Cx43 heterocellular interactions as a therapeutic target
for reducing cardiac arrhythmias.
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CHAPTER 1: INTRODUCTION
1.1 Myocardial infarction and the injury border zone – clinical problem and
significance
Heart disease is the number one killer of people worldwide, causing an estimated
17.5 million deaths in 2012 (Fig. 1-1A) [1]. Ischemic heart disease – the cause of
myocardial infarction – is responsible for over 7.2 million deaths each year (Fig.
1.1B) [2]. In the western world, cardiovascular disease (CVD) is a major health and
economic burden, responsible for three quarters of a million deaths in the United
States alone [3], with indirect costs totaling over $200 billion [3]. However, over
three quarters of deaths from cardiovascular disease (CVD) occur in low- and
middle-income countries, because of the lack of access to primary care and early
detection programs in contrast to those that are available in high-income countries
(Fig. 1.1). These health issues create a heavy economic burden on these low- and
middle-income countries. For example, the annual direct costs of CVD in China
comprise 4% of their gross national income, estimated at more than $40 billion [4].
Projections from the World Heart Federation suggest that the burden of CVD in
developing countries will rise to match that seen in industrialized countries
because of increased urbanization and the associated lifestyle changes [4,5].
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Figure 1-1. Prevalence of cardiovascular disease worldwide. A) Total number of deaths
from CVD by region in 2008. B) Total number of deaths from ischemic heart disease (which
encompasses MI) by region in 2008. Reproduced from [1].
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Commonly known as heart attack, myocardial infarction (MI) is the death of cardiac
tissue caused by prolonged ischemia [6]. It is most often caused by rupture of an
atherosclerotic plaque with thrombus formation in a coronary vessel, blocking the
blood supply to a portion of the myocardium (Fig. 1-2A). After the onset of
ischemia, cell death occurs in minutes to hours. The extent of damage can be
determined by factors such as location of the thrombus in the coronary vascular
tree, the extent of collateral circulation to the ischemic zone, preconditioning, and
reperfusion. A fully-healed infarct, as seen in Figure 1-2B, may not differentiate
until 5 to 6 weeks after the MI [6]. Infarct size in a major predictor of outcome in MI
patients [7]. Large infarcts result in extensive cardiac remodeling, including
changes in gross morphology, histology, and molecular function/interactions [8].
Part of the remodeling process after MI includes excessive collagen deposition in
the injured area of the myocardium, which prevents wall rupture, but generates a
new non-contractile tissue that can no longer actively longer contribute to the
mechanical pump function of the heart. Replacement fibrosis occurs in the area of
injured myocardium, where collagen is deposited by activated fibroblasts (aka
myofibroblasts). MI often results in reduced systolic and diastolic function and can
predispose patients to arrhythmias because of the extensive remodeling that
occurs [9]. Though an infarct may be healed by 5-6 weeks, the remodeling process
is often ongoing; with continued dilation, heart function deteriorates over time,
leading to heart failure and the eventual death of the patient [10].
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Figure 1-2. Myocardial infarction. A) A plaque rupture and thrombus blocking blood flow
to a portion of the myocardium is the most common cause of acute MI. B) An infarcted
human heart with a healing infarcted area indicated by arrows. Reproduced from [6] and
[328].

4

Bordering the infarct area is the injury border zone (IBZ), which is a few cell layerthick area of transition between the scar and the viable myocardium. The changes
in tissue electrophysiological properties, cell organization, collagen deposition, and
inefficient removal of toxic biochemical products, among other factors, can
contribute to the generation of lethal arrhythmias in the IBZ [11–13]. The structural
and biophysical changes that occur in the IBZ will be discussed in depth below.
Standard of care for acute MI is focused on restoring blood flow to the ischemic
tissue. Early treatment for MI may include oxygen therapy, aspirin and nitroglycerin
to improve blood flow, as well as treatment for pain. Thrombolytics may be
administered to dissolve the clot causing the MI, though this treatment is most
effective within a few hours of the clot forming. Coronary angioplasty may be used
acutely to open the blocked artery and a stent may be placed to maintain patency
of the blood vessel. Pharmacological treatments such as beta blockers,
angiotensin converting enzyme (ACE) inhibitors, and anti-coagulants may also be
given [14]. More patients in the developing world are surviving MI due to improved
clinical interventions, though the frequency of re-hospitalization is high [3]. While
clinical interventions for acute MI are focused on dissolving the clot and
reestablishing blood flow, there are few therapies focused on supporting healing
of the heart, let alone regeneration of lost tissue and cells.
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1.2 Structure and biophysical properties of connexins and gap junctions
The connexin proteins that form gap junctions (GJs) are thought to be responsible
for spread of electrical signals and subsequent coordinated contraction of the
heart. GJs are present in nearly all mammalian tissues, and they serve an
important function in direct intercellular communication, coordinating events in
tissues and between cells. The connexin proteins that comprise GJs are tightly
clustered together in the cell membrane, directly connecting the cytoplasm of two
cells. This cytoplasmic continuity is the property that confers a functional
syncytium. Work from Engleman in 1870 first described a functional syncytium
when he reported a wave of contraction that traveled down a ureter after
application of an electrical stimulus [15], a property later attributed to smooth
muscle cells. Later work in the heart showed the ventricles could still contract
rhythmically after being severed from innervation [16,17]. It was initially thought
that a syncytium involved fusion of a portion of the membranes of adjacent cells,
though later electron microscopy studies in mouse heart and liver showed that an
electron dense tracer added during tissue processing filled the small “gap”
between the membranes of two adjacent cells (Fig. 1-3A) [18] and in en face GJs
between two cells, the tracer outlined the hexagonal array of the GJ plaque
structure (Fig. 1-3B). It was Dewey and Barr that first suggested that these
structures were sites of electrical coupling between cells [19,20].
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GJs are comprised of connexin proteins. Six connexin proteins oligomerize to form
a connexon, or hemichannel, in the membrane of a cell. Two hemichannels from
adjacent cells dock to form a GJ channel. Tens to thousands of GJ channels
aggregate into a GJ plaque (Fig. 1-3 and Fig. 1-4A) [19,21,22]. In mammals, there
are 22 known members of the connexin family of proteins, which can combine to
form homotypic or heterotypic GJ channels (Fig. 1-4B) [23,24]. Connexins are a
membrane tetraspan protein with intracellular amino- (N-) and carboxyl-terminal
(C-terminal) domains. Within the four transmembrane domains are two
extracellular loops and one cytoplasmic loop (Fig. 1-4C). The various connexin
isoforms are named for their molecular mass, ranging in size from 25 to 60 kDa
[25,26]. Much of the four transmembrane domains are conserved, with variability
between the isoforms coming from differences in the C-terminus [25]. In the
extracellular loop domains, disulfide bonds between cysteine residues are thought
to be involved in docking of connexons between adjacent cells (Fig. 1-4C) [26],
potentially playing a role in cell adhesion. Sequence similarity between different
isoforms of the molecule allows connexins to form heterotypic channels, where the
GJ channel is comprised of a connexon of different protein isoforms contributed by
each cell (Fig. 1-4B) [27]. Sequence similarity in the transmembrane regions of the
protein allows formation of heteromeric channels, where each connexon is made
up of different isoforms of connexins (Fig. 1-4B) [28].
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Figure 1-3. Electron microscopy of GJs. A) Work by Revel and Karnovsky used
lanthanum, an electron dense tracer, that revealed the 'gap' between the two membranes
that gap junctions would come to be named for. B) The lanthanum tracer revealed a
hexagonal array structure (‘j’ and higher magnification in inset), when used on tangential
sections through the gap junction plaque. Reproduced from [18].

Molecules of less than 1 kD in size can passively diffuse through a GJ channel,
including water, metabolites, second messengers, nucleotides, and ions mediating
the spread of electrical signals [29–31]. Hemichannels, or connexon channels that
are located in the cell membrane, can also function in intracellular-extracellular
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exchange of these same molecules. While all connexins act as nonselective
channels, passage of solutes through the channel may differ between compounds
of similar chemical composition [32]. Selectivity, conductance, and gating of GJ
channels can vary slightly between isoforms of connexins, and these properties
are sensitive to voltage, chemical changes, and pH [32,33]. Other factors affecting
the permselectivity of channels include phosphorylation and formation of
heterotypic and heteromeric channels. The C-terminus and intracellular loop are
thought to be largely responsible for differences in function between different
isoforms of connexins. The C-terminus interacts with numerous proteins and
contains many phosphorylation sites that can play roles in altering intercellular
communication through direct changes in protein trafficking, distribution,
degradation, and post translational modification [26,34,35].
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Figure 1-4. Molecular structure of the GJ. A) Connexin proteins assemble into
connexons. Connexons from adjacent cells dock to form an intercellular GJ channel in the
membranes of adjacent cells. B) GJs may form heterotypic or heteromeric channels, which
can affect their permselectivity. C) Connexins have four transmembrane domains, a Cterminus that interacts extensively with other proteins, and extracellular loops with
disulfide bonds that may play a role in adhesion. Reproduced from [26,30].
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Though there are no reports discussing adhesive properties of connexins in the
heart, several studies in the nervous system detail the function of connexins in
intercellular adhesion. Cellular adhesion of a glioma cell line increased when
transfected with Cx43, and this occurred independently of GJ channel function
[36]. When antibodies directed against the extracellular loops of connexin were
added, aggregation of Cx43-expressing cells was reduced. Connexin-mediated
adhesion is also known to be required for radial migration of cells in the developing
cortex [37]. In C6 glioma cells and HeLa cells (cells which do not normally interact),
transfection of both cell types with Cx43 enabled adhesion to occur between the
cells types in a short-term suspension aggregation assay [38]. Aggregation did not
occur in untransfected cells.
In 1970, Steinberg postulated that cells could sort due to differences in intercellular
adhesion strengths [39]. In theory, cells with higher intercellular adhesion forces
would sort to the center of co-culture aggregates, leaving the cells with lower
adhesion forces on the outside. Foty and Steinberg later showed that expression
of different levels of cadherins in cells provided evidence in favor of this hypothesis,
as cells expressing higher levels of cadherins sorted to the inside of co-culture
aggregates [40]. If connexins are involved in adhesion, then different levels of
connexins between cells may also account for some level of sorting. More recent
work demonstrated that this is, indeed, the case, as altering Cx43 in multiple cell
lines led to changes in cell aggregate formation [41]. Sterically inhibiting Cx43
docking with an antibody directed against the second extracellular loop of Cx43
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slowed aggregation of cells, while enzymatic digestion of cellular adhesion
molecules and N-cadherin neutralizing antibody decreased cell aggregation a
comparable amount to inhibiting connexins. Interestingly, treating cells with Gap26
– a Cx43 mimetic peptide that blocks gap junction intercellular communication
(GJIC) but does not inhibit docking – accelerated cellular adhesion [41]. These
data provide evidence that Cx43 does indeed have adhesive properties, and it may
be that altered levels of Cx43 in the heart post-MI change patterns of cell migration
and cohesion.

1.3 Regulation of gap junction intercellular communication
Several factors influence GJIC, including plaque size, phosphorylation, and
formation of heterotypic and heteromeric channels. Additionally, there are several
known compounds and peptides that can alter GJIC.
From production through degradation of connexin proteins, the half-life of connexin
proteins is measured at 1-5 hours [42,43], though in neonatal rat ventricular
myocytes (NRVMs), it is reported to be 1-2 hours [44–46]. Regulation of GJ
formation and degradation is likely important in control of GJIC. After transcription
into mRNA, connexins are co-translated into the membrane of the endoplasmic
reticulum (ER), where protein folding occurs [47,48], disulfide bonds are formed
[49–51], and connexons are formed when individual connexin proteins oligomerize
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[52]. Oligomerization may also occur in the trans-golgi compartment [53,54].
Phosphorylation of connexins, which will be discussed in detail below, and other
post-translational modifications occur in the golgi compartment [44]. Additionally,
Cx43 is known to be trafficked to the membrane via a microtubule-dependent
mechanism [26,55].
Connexin proteins are then inserted throughout the membrane, diffuse laterally,
and are incorporated into GJ plaques [26,52,56]. In the non-junctional region
surrounding the plaque, called the ‘perinexus,’ connexon incorporation into the GJ
plaque is constrained by interaction with Zonula Occludens-1 (ZO-1; discussed
below) [57]. Single channel recordings of human Cx43 GJs expressed in a human
liver cell line showed two unitary conductance states: one at 60-70 pS and one at
90-100 pS. The decreased conductance state was correlated with Cx43
phosphorylation [58]. Formation of heterotypic and heteromeric channels leads to
complex changes in channel conductance [59–64]. For example, heterotypic
Cx43/45 channels had a conductance that was the sum of each of the hemichannel
conductances [65], while conductance of homotypic and heterotypic channels
comprised of two connexin subtypes are dissimilar [61,63,64].
Communication between adjacent cells can also be regulated by increasing the
number of channels in a GJ plaque [66]. Work from our lab showed that in Cx43expressing HeLa cells, an increase in GJIC due to increased plaque size
happened at the expense of hemichannel communication [57]. While connexons
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are likely added to the plaque by lateral diffusion in the membrane, they are
removed from the center of the plaque [67,68] as annular junctions – sections of
GJs that span both cell membranes [69,70]. GJs are then degraded by
proteasomal and lysosomal pathways [42,43,52].
Connexins are known to interact with many other proteins that affect their
trafficking, lifecycle, function, and organization. The C-terminal binding partners of
Cx43 have been shown to affect its secondary structure. Extensive reviews on the
subject can be found here: [71,72]. Figure 1-5 illustrates the binding partners of
Cx43. Work from the Gourdie lab and others suggests that accretion and stability
of GJ channels can be regulated by Cx43-interacting proteins like Src and ZO-1
[73–79]. For the purpose of relevant background for this project, we will focus on
ZO-1 interactions with the Cx43 C-terminus, as well as other interactions that can
regulate GJIC.
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Figure 1-5. Cx43 interacting proteins. Connexins interact with many proteins (bottom
half of membrane) and are phosphorylated by many kinases (top half of membrane).
Reproduced from [52].

Cx43-ZO-1 interaction plays a key role in regulating GJ organization and
remodeling and, as such, has been studied extensively [57,73–77,80–85]. Work
from our lab suggested a role for ZO-1 in the control of GJ plaque size, as ZO-1
was found primarily localized to the edges of GJ plaques in immunolabeling studies
[86]. A tool developed in our lab to investigate the interaction between Cx43 and
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ZO-1 was a peptide mimetic of the Cx43 C-terminus [77]. This peptide – αCT1 –
contains an amino (N)-terminal biotin tag, an antennapedia internalization
sequence, and the nine most extreme C-terminal amino acids – a known PDZ
binding ligand mediating interaction with the ZO-1 PDZ2 domain (Fig. 1-6). A
control peptide of the same C-terminal amino acids, but in reverse order was used
in further experiments. In these experiments, it was found that treatment of
neonatal rat cardiomyocytes with αCT1 decreased co-localization of ZO-1 at the
edge of GJs and increased plaque size [77]. This reduced interaction between
Cx43 and ZO-1 did not alter total Cx43 levels in cells, but did result in a shift in the
pools of Cx43 so that more Cx43 was located at the interface between two cells
and less was located in intracellular pools. Together, these data suggest that
Cx43-ZO-1 interaction at the GJ plaque periphery may regulate GJ size by
controlling the rate at which hemichannels transition into the GJ plaque.
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Figure 1-6. αCT1 interrupts binding of ZO-1 to the Cx43 C-terminus. A) ZO-1 normally
binds the Cx43 C-terminus. αCT1 was developed to investigate this interaction. αCT1 is a
peptide mimetic of the Cx43 C-terminus attached to an antennapedia cell-internalization
sequence. B)When added to cells, αCT1 crosses the cell membrane and bind to ZO-1,
inhibiting the interaction of Cx43 and ZO-1. Reproduced from [329].
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Further studies in our lab showed that this Cx43-ZO-1 interaction occurred at the
‘perinexus’ – a specialized domain around the GJ plaque. In this domain, it was
proposed that the function of Cx43-ZO-1 interaction is to control hemichannel to
GJ transition [57]. ZO-1 may, therefore, control the balance between hemichannelmediated communication with the outside of the cell and GJIC. Accordingly, these
studies showed that decreased Cx43-ZO-1 interaction led to increased GJmediated dye transfer between cells and decreased hemichannel dye uptake [57].
This parallels the long-held view that GJs are assembled from connexons added
at the edges of the GJ plaque [67,87].
Another important type of intermolecular interaction of the Cx43 C-terminus is that
of the numerous enzymes that can interact to phosphorylate residues of the tail.
These are involved in regulating gating of connexins. Most connexins are
phosphoproteins [88], and most phosphorylation events occur after membrane
delivery [89]. While the phosphorylation events of connexin proteins are too
extensive to be covered in depth here, the focus will be on phosphorylation of
Cx43, as this is where most study of this phenomena has been done. A metabolic
labeling

study

showed

unphosphorylated,

and

that

Cx43

progressive

arrived

at

the

phosphorylation

membrane
of

Cx43

mostly

paralleled

incorporation into GJs [90]. Along these lines, dephosphorylation of connexins has
been linked to degradation [42]. Phosphorylation plays roles in connexin turnover,
GJIC, and cell and tissue pathophysiology, though this varies by cell type [88].
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The Cx43 C-terminus has 12 serine residues and two tyrosine residues that are
known to be phosphorylated (Fig. 1-7A) [91]. The phosphorylation events of the
Cx43 C-terminus are reviewed extensively by others and can be found here:
[35,91–94]. Phosphorylation of Cx43 happens at different points throughout its
lifecycle [90,95]. Various degrees of phosphorylation lead to changes in
electrophoretic ability, and the protein separates into three major bands on
Western blots: P0, P1, and P2. P0 is non-phosphorylated, and P1 and P2 are
progressively phosphorylated and migrate more slowly (Fig. 1-7B). To some
extent, Cx43 may be phosphorylated before it is inserted into the membrane
[96,97]. Cx43 is known to be phosphorylated by non-receptor- and receptor protein
tyrosine kinases, mitogen-activated protein (MAP) kinase, and elevated cAMP
[91]. Protein kinase C (PKC) is known to increase Cx43 phosphorylation and
decrease GJIC in numerous cell types [98–101]. Previous reports in NRVMs
suggest that PKC activation increases [102] or causes no change to GJIC [103].
PKC phosphorylates Cx43 at S368 and S372. S368 is likely responsible for
reduced GJIC and changes in single channel behavior [92], as PKC activation
decreased single channel conductance of Cx43 to ~50 pS, whereas in cells with a
Cx43-S368A mutation (i.e., substitution of serine for a non-phosphorylatable
alanine (A) residue), the ~100 pS channel conductance state was present. Our lab
has shown that PKCε activity is increased by αCT1, with a subsequent increase in
Cx43 pS368 [104,105]. Though various diseases and compounds alter the
phosphorylation status of Cx43, the biophysics of this process is not well
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understood. For example, pS368 is often associated with the P0 band in Western
blots, though it is unknown when this event occurs and whether this alters GJ
plaque structure.

1.4 Cardiac tissue organization and function in the normal heart
Myocytes are responsible for the contractile function of the heart, while fibroblasts
serve to generate the extracellular matrix (ECM) on which the heart is organized.
While myocytes comprise up to 75% of the volume of the heart, non-myocytes are
far more numerous, accounting for nearly two thirds of cells by number in rat [106]
and human [107,108], although these cells may only account for 30% of cells by
number in mice [109].
Myocytes are organized into sheets that are 3-5 cells thick and these muscle layers
can slide against each other during ventricular contraction. ‘Fiber orientation’ or
the orientation of myocytes along their long axis, varies from -45 in the epicardium
to +45° in the endocardium relative to the ventricle horizontal plane [110,111].
Connexins are located primarily at the IDs on the short ends of myocytes, with
some localized to lateral myocyte borders (Fig. 1-8A). This arrangement promotes
anisotropic propagation of electrical signal through the myocardium [112].
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Figure 1-7. Cx43 C-terminal phosphorylation sites. A) There are many
phosphorylatable amino acids on the Cx43 C-terminal tail. Each is highlighted here in
colors corresponding to the enzyme responsible for its phosphorylation. B)
Phosphorylation events are associated with changes in electrophoretic mobility of Cx43,
and three bands result on Western blots. The P0 band migrates fastest and is thought to
correspond to nonphosphorylated Cx43. The P2 band migrates slowest and incorporates
multiple phosphorylation events. P1 is an intermediate band. Reproduced from [91] and
[35].
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Figure 1-8. Connexin organization in the heart. A) Cx43 is localized primarily at the
intercalated discs (IDs), and electrically connects adjacent myocytes. Inset: Cx43 is
present in higher density at GJ plaque edges. B) Connexins 40, 43, and 45 are all found
in heart and their expression varies by region of the heart, with Cx43 being the
predominant connexin in the ventricle. Reproduced from [330].
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Connexins in the heart are thought to be responsible for the spread of electrical
signals. Conduction starts in the sino-atrial (SA) node and travels through the atria
to the atrio-ventricular (AV) node. Here, conduction is delayed while the ventricles
are filled, then electrical activation is propagated though the His-Purkinje system,
down to the apex of the heart. Waves of excitation then travel from the apex up to
the base through ventricular myocardial tissues, being conducted through
myocytes that are highly interconnected at IDs. The ID allows for sequential
activation and contraction of the muscle syncytia by allowing the passage of ions.
The mammalian heart contains three types of connexin proteins in abundance:
Cx40,

Cx43,

and

Cx45

[113–116].

Local

conduction

differences

and

electrophysiological properties in the heart are thought to be largely accounted for
by the variation in connexin distribution (Fig. 1-8B) [116]. Analysis of connexin
localization using myocyte and fibroblast specific markers in rabbit ventricle
showed that 95% of Cx43 was associated with myocytes, 7% with fibroblasts, and
3% was found at the interface between the two cell types (Fig. 1-9A) [117].
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Figure 1-9. Cx43 localization in the ventricle in normal heart and disease. A) In the
normal heart, Cx43 (green) is highly expressed in myocytes (red). Fibroblasts (blue) also
express some amount of Cx43 and can interact with myocytes via this protein. Vertical
arrows show myocyte-myocyte connections (MM), horizontal arrows show fibroblastfibroblast (FF) connections, and angled arrowheads show MF connections. B) In the injury
border zone (IBZ) of infarcted myocardium, Cx43 organization is disrupted and is
increasingly found in myocyte-fibroblast interactions (left arrowhead), and in fibroblasts
(angled arrowhead). Reproduced from [331] and [173].

While the long-held view of electrical activation in the heart involves ion transport
through GJs, ephaptic coupling – in which local ion concentration gradients are
responsible for activation of adjacent cells – may also play a role [118]. Studies
from our lab have demonstrated the presence of the cardiac voltage-gated sodium
channel, Nav1.5, in the perinexus along with other structural, functional, and in
silico data that provides evidence for this non-electrotonic form of coupling in the
heart [119,120]. Computer models have shown that ephaptic effects may be seen
in all areas of extracellular space, not just at the IDs between myocytes [121],
leaving open the possibility for fibroblast involvement.
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Cardiac fibroblasts are organized into thin sheets, interspersed between myocytes
in the myocardium. Fibroblasts in situ have a large surface area, with electron
microscopy studies estimating their surface area at >1500 µm2 [122]. A large
membrane surface area would enable fibroblasts to extensively interact with
adjacent cells.
Cardiac fibroblasts were once thought of as a homogeneous population of cells,
though recent studies have shown that these cells of mesenchymal origin derive
from a number of sources. The majority of fibroblasts derive from the proepicardium [123]. Fibroblasts also originate from the epicardium and endothelium
by epithelial-to-mesenchymal transformation (EMT) [124,125] and endothelial-tomesenchymal transformation (EndoMT) [126–128], respectively, though the
species-specific relative contribution of these populations is presently unknown.
One caveat to studying cardiac fibroblasts that may directly relate to their
developmental heterogeneity is the lack of a marker that is inclusive and specific.
Proteins that have been used to identify fibroblasts – of both normal and activated
phenotypes – include discoidin domain receptor tyrosine kinase-1 (DDR2)
[129,130], vimentin [131–133], Transcription factor-21 (TCF21) [134,135],
fibroblast specific protein-1 (FSP1) (which has turned out not to be fibroblast
specific) [136], fibroblast activation protein (FAP) [137–139], Wilm’s Tumor 1
(WT1), and α-smooth muscle actin (αSMA) [140,141]. Lack of a specific marker
has made studying these cells in health and disease challenging. While one of the
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primary functions of a fibroblast is to produce collagen, few studies have used this
as a benchmark for identifying fibroblasts in either health or disease, though more
recent studies have demonstrated the utility of collagen as a genetic marker of
cardiac fibroblasts [141].
Fibroblasts, as a mesenchymal cell, have been pegged as having the primary
structural role of producing the ECM ‘skeleton’ of the heart into which the cardiac
cells are organized. While this function is required for maintenance of the normal
myocardium, and for preventing rupture of the infarct area due to myocyte death
after myocardial infarction, fibroblasts are known to have many other roles.
Fibroblasts are extensively involved in biochemical signaling in the heart (reviewed
here: [142–144]), but also contribute to electro-mechanical signal transduction
[145,146], and can be electrotonically coupled to myocytes [21,147–149], as
fibroblasts have been shown to express Cx40, 43, and 45 [150,151]. The field of
myocyte-fibroblast electrotonic coupling, while far from new (some of the first
reports of myocytes coupling to non-myocytes were by Goshima [152] in the late
1960s), still has a lot of open questions.

1.5 Changes in the post-myocardial infarction heart
The myocardium does not have the ability to regenerate, so after MI, the significant
loss of cardiac muscle is replaced by a scar. The healing response in the
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myocardium has been reviewed extensively elsewhere (see: [153,154]). A brief
review will follow. Cells in the ischemic area of the myocardium die and cardiac
repair begins with the inflammatory response that clears the infarcted region of
tissue of dead cells and debris and provides the proper biochemical signaling to
heal the infarct. Fibroblasts are activated in the process and migrate into the wound
to replace the lost myocytes and deposit excess ECM. This healing and scarring
response, as in other wounds in the body, changes over time, though it rarely
reaches an equilibrium state as this type of scarring injury is generally associated
with declining (and irrecoverable) cardiac function. As the heart is less able to
efficiently pump due to the loss of myocytes, the heart begins to dilate and
myocytes hypertrophy, a process that can eventually deteriorate into heart failure
– an ultimately fatal disease [6].
Fibroblasts post-MI release chemotactic factors like transforming growth factor-β
(TGF-β) that recruit inflammatory cells into the ischemic tissue and activate
fibroblasts [155–158]. Activation of fibroblasts leads to transdifferentiation to
myofibroblasts and includes an initial increase in proliferation and migration,
followed by increased synthesis of ECM proteins [159]. While this helps prevent
the heart wall from rupturing after MI, these changes can alter normal conduction
through the heart [160]. As described in the previous section, fibroblasts in the
heart comprise a heterogeneous population of cells. Recent studies in various
injury models have shed some light on the contribution of these relative
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populations to pressure overload-induced fibrosis in the heart [141,161], though it
is presently unknown how these populations contribute to healing after MI.
Bone marrow derived cells are known to be recruited to the site of injury in many
tissues in the body. Several studies of MI suggest that bone marrow derived cells
make a large contribution (up to 60%) of fibroblast-like cells in the scar [162–165],
though there is some debate as to whether the labeled cells in these models truly
represent bone marrow derived cells.
The IBZ is often the site of reentrant arrhythmia generation and there are several
structural factors that contribute to this, including changes in cell and tissue
organization and changes in Cx43 distribution. While the myocytes in the ischemic
area die and are replaced with fibroblasts and the ECM these cells deposit, some
of the myocytes in the IBZ survive. Structural remodeling in the IBZ involves an
interspersion of myocytes with fibroblasts and ECM, leading to separation of
myocytes and increased coupling between myocytes and fibroblasts (Fig. 1-9B)
[11,166,167]. Additionally, increased deposition of ECM proteins leads to an
altered structure that can separate cells, interrupting patterns of electrical coupling.
Alterations in cell organization and coupling may contribute to the arrhythmogenic
propensity of the IBZ [168].
In addition to reorganization of cells and increased deposition of ECM proteins
post-MI, Cx43 reorganization to the lateral borders of myocyte membranes in the
IBZ, as seen in Figure 1-9B, is thought to contribute to arrhythmias [112,169–171].

28

One of the alterations in fibroblasts post-MI is an increase in connexin expression
[167,172,173], which increases the ability for fibroblasts to be coupled to myocytes
via GJs [167]. While myocyte-fibroblast coupling is relatively rare in the uninjured
myocardium, immunolabeling studies show that this coupling is increased in the
IBZ (Fig. 1-9) [173,174]. In multiple experimental animal models, conduction
slowing is measured in the IBZ and scar [104,160].
In addition to its known function in transmission of electrical signals in the heart,
Cx43 is known to be involved in the spread of injury signals. GJs in skin are
implicated in the spread of injury signals [175], and are involved in inflammation,
wound closure, and scarring (reviewed here: [176,177]). Accordingly, the
knockdown of Cx43 in mouse skin has led to smaller wound sizes and faster rates
of closure [178]. In our lab, application of the αCT1 peptide to excisional skin
wounds in rats and pigs led to shorter times to wound closure and scar tissue with
more normal histo-architecture [179]. This peptide has completed Phase I and
Phase II clinical trials for wound healing in chronic non-healing diabetic foot ulcers
[180] and venous leg ulcers [181], where the peptide led to significant decreases
in ulcer size versus standard of care treatment alone. In other studies from our lab,
cryo-injury size was increased in streptozotocin (STZ) diabetic mice compared to
control mice receiving insulin, and this increase in injury size was associated with
a decrease in Cx43 pS368 [182], suggesting that Cx43 pS368 is likely decreasing
the conductance state of GJ channels and the subsequent injury spread in the
heart.
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A decrease in GJIC has been observed in the myocardium post-MI [183]. After
ischemia or during cardiac hypertropy, density of GJs decreases in the ischemic
area compared to the remote regions of myocardium [184]. Changes in GJ
distribution in the IBZ seem to contribute to reentrant arrhythmia generation [185].
Decreased electrical coupling during acute MI has been correlated with
dephosphorylation and reorganization of Cx43, as well as translocation from the
cell surface to intracellular pools [186,187].
In the population of Cx43 that remains at the ID in an ischemic setting, there is an
increase in phosphorylation at S368 (Fig. 1-10) [94]. Additionally, ischemic
preconditioning

has

been

shown

to

increase

PKCε–mediated

Cx43

phosphorylation of S262 and S368, and prevent Cx43 lateralization following an
ischemic insult [188]. Phosphorylation events in Cx43 are known to regulate
channel effects like unitary conductance, so it may be that communication is
reduced as a protective mechanism against injury spread from the ischemic area.
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Figure 1-10. Cx43 phosphorylation in ischemic disease. Cx43 that is phosphorylated
at serine 368 (pS368) is maintained at the IDs in ischemic conditions while Cx43
reorganizes to the lateral myocyte borders. Reproduced from [94].

1.6 Attempts to heal the heart
Cardiac disease models
Models of cardiac disease – both in vivo and in vitro – are used extensively in
research not only to better understand disease processes, but also as a model for
testing pharmaceutical compounds. The commonly used left anterior descending
(LAD) coronary artery experimental model of acute MI in mice is closely
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representative of ischemic cell death as seen in humans [189,190]. However, due
to differences in branching of the coronary arteries and collateral circulation in
rodents, this model often leads to differences in size and shape of the infarct area
and scar [191]. First reported by van den Bos and colleagues [190], a cryo-injury
model of infarction is generated by creating an injury area by freezing the left
ventricle. While the mechanism of cell death is different in the cryo-injury model
from the ischemic model, cryo-injury creates an extensive IBZ that is a few cell
layers thick, and an injury that is of repeatable size and shape, making it ideal for
testing therapeutic compounds targeted at altering IBZ properties. More clinically
relevant models include dog, pig [192,193], and sheep infarction [194], since these
animals are closer to humans in size, structure, and heart rate. However, these
large animal models are expensive, low throughput, and time consuming.
Many in vitro models have been used to study cardiac disease processes. These
models use NRVMs, embryonic chick myocytes, human embryonic stem cellderived cardiomyocytes, and induced pluripotent stem cell (iPSC)-derived
cardiomyocytes [195]. These models include natural hydrogel-based models,
synthetic scaffold-based models, and microdevice-based models [196]. An
advantage of iPSC cardiac disease models is that they can often reproduce
genetic cardiac diseases, as has been observed with familial dilated
cardiomyopathy [197] and familial hypertrophic cardiomyopathy [198]. More
recently, in vitro models of cardiac disease have been used to test pharmaceutical
compounds that are already used clinically in order to develop models relevant to
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certain cardiac disease conditions. Human iPSCs have been used to test both an
ion channel blocker (verapamil) [199] and a β-blocker (metoprolol), using beat rate
and mechanical motion to assess cardiac tissue function. Additionally, another βblocker (isoproterenol) and a human Ether-à-go-go-Related Gene (hERG) blocker
(E-4031) were tested in this model [200]. However, further development of these
models for testing of pharmaceutical compounds relevant to cardiac disease is
needed.

Cardiac tissue engineering
Nearly 20 years ago the first engineered cardiac tissues were created from
embryonic chick cardiomyocytes [201]. The field has seen immense growth since
then with hundreds of papers being published each year on the subject, including
the first report of cell sheets being implanted in a patient [202]. The history,
development, and state of the art of this field have been reviewed extensively
elsewhere (see: [203,204]). The following is a brief summary on the successes and
challenges of the various techniques used to engineer cardiac tissue.
Cardiac tissue engineering has its roots in culture of aggregated cardiac cells,
generated by rotating culture by Moscona in 1959 [205]. These heart cells formed
heart-like tissue that generated beating aggregates.
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Hydrogels have been used since the 1980s and include a gelling matrix of natural
proteins like collagen or Matrigel in a casting form [201]. These proteins induce
cells to spread and form intercellular connections. The cells can contract and
remodel the matrix in which they reside. Hydrogels that are anchored induce
alignment of cells and enable constant mechanical strain of engineered tissues.
The first anchored studies demonstrated the importance of mechanical forces in
alignment of cells and proper engineered tissue development [206]. More recent
studies have shown that electrical stimulation can also induce proper cell
alignment and development of tissue structure [207].
A classical engineering approach to cardiac tissue engineering involves creation
of a prefabricated matrix that is seeded with cardiac cells or cardiac progenitor
cells. Various materials used to create matrices include natural and synthetic
materials like alginate [208] and collagen [201], or polyglycolic acid [209], and polyL-lactic acid/polyglycolic acid composites [210], among others. These matrices can
be made to any dimensions and easily manipulated in culture. This being said,
synthetic scaffolds are challenged by limited diffusion capacity, inability to be
remodeled (though some can be degraded), and toxic degradation products.
Decellularizing whole hearts with detergents that do not affect matrix structure can
provide natural cues to cardiac cells or cardiac progenitor cells for repopulation,
though repopulation of these structures has proven difficult [211].
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Temperature-sensitive coatings on culture dishes allows cells to be grown in
sheets and then detached [212]. These sheets can be stacked to generate beating
3D tissues. While this scaffold-free technology generates a tissue that is suitable
for transplantation, these tissues can be difficult to manipulate because of their
mechanical properties. However, this technique continues to be developed for
cardiac repair [213,214].
In addition to mechanical strain and electrical signals, in vitro development of
cardiac tissues has indicated the importance of non-myocytes in the formation of
functional tissues. Tissues using a combination of myocytes and fibroblasts
develop higher forces [215] and better tissue structure and electrical activation
threshold [216].
Another approach to cardiac tissue engineering involves injection of cells in a
matrix in situ and relies on native signaling within the myocardium to induce
differentiation and maturation of injected cells [217]. Many of these techniques
have been used in some variation or combination to create engineered cardiac
tissue. However, there are remaining challenges to developing and treating an
injured heart to regain function, including cell sourcing, standardization of
protocols, serum-free culture, tissue maturation, and testing to ensure consistency
across various methods [204].
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Pharmaceutical development
There a great number of pharmaceutical compounds used for cardiac disease.
General classes of these drugs include anticoagulants, antiplatelet agents, ACEinhibitors, angiotensin II receptor blockers, angiotensin receptor neprilysin
inhibitors, β-blockers, combined α- and β-blockers, calcium channel blockers,
cholesterol lowering medications, digitalis preparations, diuretics, and vasodilators
[218]. In 2010, global market sales reached $170 billion for cardiovascular drugs
alone and growth was projected to hit $187 billion by 2016 [219]. Development of
new drugs, however, is expensive and inefficient. For most compounds, it takes
over a decade of research and nearly $5 billion per drug [220–222]. Additionally,
in order to launch a single drug per year, 9 compounds on average need to enter
Phase I clinical trials, 5 need to enter Phase II, and 2 need to enter Phase III trials
[221].
Before drugs reach the preclinical animal-testing phase, they are typically
screened in vitro using established and well-characterized cell lines. 2D in vitro
cultures are not representative of the 3D tissue microenvironment in either health
or disease, making this a poor model for investigation. Additionally, preclinical
animal models are expensive, poorly predict outcomes due to interspecies
variation in cardiac electrophysiology [223,224], and have led to drugs being
withdrawn from the market because of previously unobserved cardiotoxic effects
[225,226]. Human heart cells and tissue would provide more relevant models, but
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are difficult to obtain and challenging to maintain in culture, so they are an
unrealistic testing platform [227].
There is a great need for design of new testing platforms with the goals of reducing
cost and time to approval, decreasing the number of drugs that make it past
approval and are then removed from the market because of toxic effects, and
reducing side effects. In the last 20 years, the US Food and Drug Administration
approved 113 drugs for cardiology and vascular diseases, many of them generics
of drugs that had come off patents [228]. Not a single one of these drugs is aimed
at healing the heart, restoring lost cardiac function, or regenerating the
myocardium. Much preclinical testing directly targeting regeneration or diseaserelated signaling cascades exists [229]. A combination of these new therapies and
development of novel testing platforms has the potential to transform the
development of cardiovascular therapeutics.

The effect of Cx43 C-terminal mimetic peptide on the healing heart
We adapted the cryo-injury model for use in our lab [104], and we have determined
that it produces an injury of reproducible size and shape, making it useful for testing
of therapeutic compounds as fewer animals can be used to detect differences
between treatments. We have shown that treatment of a murine cryo-injury with
αCT1 led to reduced LV dilation, fewer inducible arrhythmias, lower arrhythmia
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severity scores, increased ventricular depolarization times, and maintenance of
Cx43 at intercalated discs between myocytes, which was associated with an
increase in Cx43 pS368 [104,230].
To further investigate the changes in the myocardium that could be responsible for
the improvements in physiological function, TTC staining of hearts 8 weeks after
cryo-injury showed a trend of decreased scar volume for αCT1-treated hearts
relative to reverse peptide and vehicle controls [231]. The difference was
significant (p < 0.02) for the αCT1 and reverse comparison. Images through the
base-apex axis along the middle of each scar were used to quantify scar depth
and thickness of underlying myocardium. There was a trend of decreased scar
depth and increased depth of underlying myocardium for αCT1-treated hearts, but
the differences between treatment and controls were not significant.
Masson’s trichrome staining of histological sections of the scar also indicated that
fibrous organization of the scar in αCT1-treated hearts was more uniform than in
control mice (Fig. 1-11A) [231]. This was seen as a more regular pattern of
collagen deposition and increases in collagen alignment along the scar. Vascular
structures in the scar tissue appeared to increase scar non-uniformity by acting as
obstacles that caused local variations in the orientation of collagen fibers.
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Figure 1-11. Masson’s trichrome images of cryo-injured hearts indicates a more
uniform scar structure. A) αCT1 treated hearts (bottom) show a more uniform fibrous
structure than reverse inactive peptide controls (top). B) This was quantified by examining
parameters of the scar substructure. While no differences were seen between αCT1 and
controls in scar thickness, collagen density, or fiber orientation, the coefficient of variation
(COV) of these measurements was significantly lower in αCT1-treated hearts compared
to controls, meaning scars were more uniform. While COV of vascular density did not differ
between groups, the vascular density was significantly reduced in αCT1-treated hearts
versus controls – a factor that may contribute to more uniform collagen fiber orientation.
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A survey of scar structure parameters showed that scar thickness (measured as
the epicardial to endocardial thickness through multiple points along the scar) was
not significantly different between groups (Fig. 1-11B). Collagen density was
measured as the area of collagen tissue normalized to total scar area in Masson’s
stain. Collagen fiber orientation was measured at 20 different points within the
scar. None of these measurements were significantly different between treatments
and controls.
We measured the coefficient of variation (COV = SD/mean) of each of these
measurements (Fig. 1-11B). The COV of scar thickness is significantly reduced in
αCT1-treated scars compared to controls, meaning that scar thickness is more
uniform. The COV of collagen density is lower in αCT1-treated hearts, meaning
collagen density is more uniform. The COV of collagen fiber orientation is lower in
αCT1-treated hearts compared to controls, meaning collagen is more organized in
a uniform direction. In all of these parameters, αCT1-treated hearts showed less
variation than either reverse or vehicle controls. This suggests that, in hearts
treated with αCT1, scars were more uniform. We measured vascular density and
the COV of vascular density and found fewer vessels in the αCT1-treated scars. It
may be that this reduction in vascular density is one of the reasons for lower
variation in collagen orientation, as with decreasing vessel density, there are fewer
structures for collagen fibers to negotiate. Overall, the quantitative data indicated
that the histo-architecture of 8-week LV cryo-scars in αCT1-treated hearts was
more uniform than that of controls.
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At 8 weeks after cryo-injury, a definite IBZ approximately 5-10 myocyte diameters
wide differentiated adjacent to cryo-injury scars. This narrow zone of myocardial
cells exhibited increases in MLC2a immunolabeling and this was significantly
increased in αCT1-treated hearts compared to controls (Fig. 1-12A,B). The IBZ
was also characterized by interdigitation of collagen fibrils projecting from the scar
between border zone myocytes (Fig. 1-13A). There were striking differences in IBZ
structure between αCT1-treated and control hearts. In picrosirius red staining of
control mice, collagen tended to interdigitate in fine patterns between myocytes in
the IBZ, while in the IBZ of αCT1-treated hearts, groups of myocytes appeared
grouped together in coherent bundles, with myocytes less separated by strands of
interstitial collagen than in controls (Fig. 1-13A). Additionally myocytes in the IBZ
in αCT1-treated hearts appeared to be slightly larger and more uniformly sized
than controls (Fig. 1-13B). When quantified in a 4 cell-thick layer adjacent to the
scar, αCT1-treated hearts also showed significantly decreased variability (COV) of
IBZ myocyte width (Fig. 1-12B). There was a tendency for the mean size of IBZ
myocytes to be increased in the αCT1 group, but this trend was not significant
(data not shown). The extent of both MLC2a immunolabeling was also significantly
increased in the IBZ myocardium of the αCT1-treated group, as compared to
control (Fig. 1-13A,B).
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Figure 1-12. αCT1 treatment of cryo-injured hearts alters myocytes. A) αCT1-treated
hearts (right) have an increased expression of Mlc2a in the IBZ 8 weeks after injury
compared to controls (left). B) αCT1-treated hearts have an increased expression of Mlc2a
(left), are comprised of a higher percentage of myocytes (center), and have more uniform
myocyte size than control hearts (right). C) Reduced collagen density and less variation
in myocyte size in the IBZ are associated with reduced systolic dilation. These histological
changes are seen in αCT1-treated hearts.
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Figure 1-13. αCT1 alters cell organization in the IBZ. A) Picrosirius red staining of scars
revealed collagen deposition that separates individual myocytes in CTRL hearts, and this
occurred to a lesser extent in αCT1-treated hearts. B) Mlc2a labeling of myocytes in the
IBZ indicated more cohesive bundles of myocytes in αCT1-treated hearts while in CTRL
IBZ, myocytes appear to be separated by non-myocytes.
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Both echocardiography and scar morphometry were undertaken on mice subject
to the cryo-injury. If we look at how these histological changes correlate with
changes in physiological function, we find significant positive correlations between
LV systolic dilation and collagen density, as well as LV systolic dilation and the
coefficient of variation of myocyte width in the border zone (Fig. 1-12C). The first
correlation may reflect that with increased collagen density the ability of the heart
to dilate at systole is being impaired. More uniform myocyte size was also found
to correlate with LV systolic dilation. A more uniform myocyte size signifies less
variation in the contractile ability of these myocytes in the IBZ, and more even
application of mechanical forces. Overall, this suggests that a lower collagen
density in the scar and a lower variation in myocyte width in the IBZ are associated
with improved physiological outcomes and both of these are changes seen in the
αCT1-treated hearts.
Overall the changes in cell organization and scar profile the IBZ with αCT1treatment raised the question as to whether αCT1 was altering cellular interactions
in a way that led to improved physiological outcome.

Study objectives and rationale
Our objective is to develop an in vitro model of the IBZ that can be 1) validated
against an animal model of infarction, 2) used as a platform for high-throughput
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testing of potential therapeutic candidates to target the IBZ, and 3) used to gain a
better understanding of heterocellular interactions in IBZ.
The rationale for these studies is the need for disease-relevant and tissue
structure-relevant in vitro testing platforms for candidate compounds and the lack
of understanding of how heterocellular interactions render the IBZ a pro-arrhythmic
substrate. Important design criteria for in vitro testing of pharmaceutical
compounds of relevance to cardiac disease include: 1) A disease model system
that sufficiently recapitulates key aspects of the cardiac disease; and 2) A disease
model system that can accurately reproduce the drug response seen in vivo.
Chapter 2 describes the development and validation of our novel model of the IBZ.
It covers changes that we see in the model that reflect the changes in a cryo-injury
model of infarction in mouse and begins exploration of the mechanism behind
these changes.
Chapter 3 describes the conduction-related changes in cryo-injured hearts treated
with our Cx43 mimetic peptide in the presence of varying extracellular ion
concentrations, the contribution of recruited bone marrow cells to the healing IBZ,
and the effect of the peptide on GJIC.
Chapter 4 describes the changes in myocyte-fibroblast interactions via Cx43 in
vivo and in vitro and examines the GJ plaque sub-domain organization.
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Chapter 5 is a stand-alone chapter. It briefly examines the role of Cx43 in healing
and regeneration of skeletal muscle, and serves as a proof of principle in
modulating the immune response to skeletal muscle satellite cells for muscle
regeneration.
Chapter 6 contains conclusions, discusses challenges and limitations, and gives
future directions and recommendations.

Significance and innovation
Generation and validation of a novel in vitro IBZ model will provide a platform that
enables us to better understand heterocellular interactions in the IBZ and the basis
for future testing of novel therapeutic compounds. While 3D models have been
used extensively to study tumor microenvironment and treatments, to our
knowledge, no studies have been done in a 3D model of cardiac cells to examine
cellular interactions. This project addresses a critical barrier to progress in
development of cardiovascular therapeutics focused on regeneration and altering
intercellular interactions. Successful completion of this project will change our
knowledge of the disease state and will provide a better model for testing of
therapeutics for post-MI patients that is directed at disease mechanism.
These studies are innovative in that they seek to challenge the clinical paradigms
by shifting treatment from a focus on prolonging life of post-MI patients to one of
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cardiac regeneration and understanding mechanisms that go beyond attempting
to stabilize cardiac function. A goal of this work is to also shift current research
paradigms for drug development to using more clinically relevant models of
disease for testing of therapeutic compounds. This has the potential to decrease
cost by finding better treatments, making additional and ongoing treatments for
patients unnecessary, and also to identify and remove non-efficacious or toxic
compounds in development more quickly, reducing the cost of the drug
development pipeline. These studies will accomplish this by creating novel
methods for analysis that could lead to further development of instrumentation.
Some of these methods are novel to the cardiovascular field, having been used in
other fields for therapeutic development, while others are novel across all fields.
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CHAPTER 2: DEVELOPMENT AND VALIDATION OF A NOVEL IN VITRO
MODEL OF THE CARDIAC INJURY BORDER ZONE

2.1 Introduction
The leading cause of death in the Unites States is cardiovascular disease (CVD),
which was responsible for 787,000 deaths in 2011 [3]. Myocardial infarction (MI)
alone caused over 157,000 deaths in 2011. Estimated direct and indirect costs of
heart disease in 2010 was $204.4 billion, with MI being one of the most expensive
diagnoses ($11.5 billion) [3]. While current clinical interventions have increased
patient survival [3], there are few new candidate compounds for cardiovascular
disease [232], not to mention the lack of available drugs focused on restoring heart
function [229]. To shift treatment of cardiac disease from a focus on prolonging life
to a focus on curing disease, development of new compounds directed at
underlying disease mechanisms is critical. Until we understand disease
mechanism better, have more disease-relevant models for evaluating drugs, and
develop mechanistically based drugs, the therapeutic pipeline will continue to be
challenged by a low number of candidate drugs.
Mechanistically speaking, the injury border zone (IBZ) – typically no more than a
few cell layers thick – is often the site of lethal arrhythmia generation [11,233].
While cellular heterogeneity at the border zone is a critical predictive factor for
arrhythmogenesis [234], the mechanism of this contribution remains to be
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understood. Altered patterns of Cx43 protein [233] and changes in organization of
myocytes and fibroblasts are key variations of the IBZ compared to healthy
myocardium [173], though how these changes contribute to the re-entrant
arrhythmias that occur at these pathogenic tissue loci remains to be understood.
Our lab previously showed the effects of a Cx43 C-terminal mimetic peptide (αCT1)
on healing of a cryo-injury model of infarction [104]. αCT1-treated hearts showed
reduced LV dilation, fewer inducible arrhythmias, lower arrhythmia severity scores,
increased ventricular depolarization times, and maintenance of Cx43 at
intercalated discs between myocytes [104,230]. Examination of patterns of
collagen deposition and myocyte and fibroblast localization in the IBZ of cryoinjured hearts displayed a difference in patterns of cell organization (Chapter 1). It
may be that αCT1 is altering heterocellular interactions in the IBZ in a way that
decreases arrhythmogenesis, though this needs to be investigated directly.
While animal models of infarction are used extensively and can accurately
recapitulate important aspects of human disease (i.e. arrhythmias), these models
are expensive, time-consuming, and low-throughput. These models are also not
feasible for initial screening studies. Before drugs reach the pre-clinical animal
model stage, extensive in vitro testing is involved in screening new candidate
drugs, though most of this is done on cell lines in 2D culture, which is far from
representative of actual human tissues. Frequently, drugs that demonstrate
effectiveness in these systems are not clinically effective and contribute to the
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meager 16% of compounds that make it through drug development and into the
clinic and market [235].
In vitro testing allows direct control of cell types and can readily accommodate coculture models. Unlike in vivo systems, where many cell types are involved and
cannot be controlled, in vitro co-culture models allow isolation of effects based on
interactions of specific cell types. Additionally, 2D in vitro systems lend themselves
to simple methods of examining cell interactions by technologies such as live cell
imaging. While 2D cultures have a limited ability to simulate 3D tissue processes,
development of a 3D in vitro heterocellular model of the IBZ would greatly
contribute to the drug development pipeline and would provide a platform to
examine myocyte-fibroblast interactions in disease. Development of a model that
simulates disease-relevant tissue processes may help screen out ineffective
compounds before they reach the expensive pre-clinical stage, leading to huge
cost savings in drug development.
The objective of the present study was to: 1) Develop and optimize a 3D in vitro
model of the IBZ using primary cardiac cells; 2) Validate this model against known
parameters of the IBZ; and 3) Evaluate the response to a small peptide therapeutic
that was previously shown to improve cardiac function after experimental MI in
mice [104]. This model is optimized to generate large numbers of technical
replicates that are highly reproducible, to create aggregates of cells that are
sufficiently small so they are not subject to necrotic cell death from oxygen
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starvation, and to allow high-throughput live imaging in order to obtain relevant
time-dependent data when testing a therapeutic compound. This model may be
used as a platform to study new compounds.

2.2 Methods
Preparation of HeLa cell aggregates in rocking culture: HeLa and HeLa-Cx43 cells
were cultured in DMEM (Hyclone) supplemented with FBS (Hyclone), 10 U/ml
penicillin and 10 µg/ml streptomycin (Hyclone), and 2 mM L-alanyl-L-glutamine
(Gibco) and maintained in an incubator at 37°C, 5% CO2. HeLa and HeLa-Cx43
cells were mixed 1:1, seeded at 1x106 cells/well in agarose-covered chamber
slides, and rocked at 0.25, 0.5, or 1 Hz. Media was changed daily. To image,
aggregates were removed from wells, washed in PBS, fixed for 10 minutes at room
temperature in 4% paraformaldehyde, washed in PBS, dried on gasketed slides,
mounted in SlowFade Gold reagent (Life Technologies), and imaged on a Leica
SP5 laser scanning confocal microscope (LSCM).
Preparation of acrylamide and agarose micromolds: Micromolds (24-96 – small
spheroids) from microtissues.com were filled with 2% UltraPureTM Agarose (Life
Technologies) in normal saline. Molds were extracted and equilibrated in myocyte
complete medium for 3 medium changes. For acrylamide micromolds, a 20%
acrylamide mix was made of acrylamide stock, bis-acetate, PBS, water, and
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TEMED. Fresh 2% ammonium persulfate was added and solution immediately
pipetted into the micromolds and allowed to gel. Acrylamide micromolds were
sterilized with 70% ethanol, rehydrated in PBS, and equilibrated with myocyte
complete medium before use.
Cell seeding and culture in micromolds: H9C2 cells (ATCC), an embryonic rat
myocardium-derived cell line, were cultured in DMEM High glucose (4500 mg/L)
with sodium pyruvate (110 mg/L) (Hyclone) supplemented with 10% FBS
(Hyclone), 10 U/ml penicillin and 10 µg/ml streptomycin (Hyclone), and 2mM Lalanyl-L-glutamine (Fisher) and maintained in an incubator at 37°C, 5% CO2.
Aggregates were labeled with CellTracker Orange (CMRA) (Life Technologies),
and seeded at 1,440-324,000 cells per micromold. This should result in aggregates
from 50-300 µm diameter. To image, aggregates were spun out of the micromolds
at 800 rpm for 5 minutes, washed in PBS, and resuspended in glycerol on a
depression slide, or in a home-built gasket slide, making the gasket as thin as
possible to accommodate the aggregates but still be able to image. Cells were
then imaged on a Leica SP5 and aggregate diameters were measured from these
images.
Cell isolation and labeling: Primary cardiac neonatal rat ventricular myocytes and
neonatal rat ventricular fibroblasts (NRVFs) were isolated from 2-day neonatal rats
by digestion in trypsin (Worthington), Pancreatin (Fisher), Collagenase II
(Worthington), and elastase (Fisher) in HBSS (Hyclone). Cells were separated on
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a Percoll (GE Healthcare) gradient, and washed. Fibroblasts were seeded and
cultured in DMEM (Hyclone or Gibco) supplemented with FBS (Hyclone), 10 U/ml
penicillin and 10 µg/ml streptomycin (Hyclone), and 2 mM L-alanyl-L-glutamine
(Fisher) and maintained in an incubator at 37°C, 5% CO2. Myocytes were labeled
immediately in 2.5 µM CellTracker Orange (CMRA) (Life Technologies) in
OptiMEM (Gibco) for 30 minutes and washed in myocyte complete medium (M199
supplemented with 0.16% glucose (Sigma), 1x MEM vitamins (Gibco), 1x NEAA
(Gibco), 1x MEM Amino acids (Gibco), 10 U/ml penicillin and 10 µg/ml
streptomycin (Hyclone), 10% horse serum (Gibco), and 5% FBS (Hyclone).
Myocytes were seeded at 30,000 cells per mold and allowed to aggregate for 48
hours. Before seeding, fibroblasts were washed in PBS, labeled with 2.5 µM
CellTracker Green (CMFDA) in OptiMEM (Gibco) for 30 minutes and washed in
fibroblast medium. Fibroblasts were added at 48 hours at 30,000 cells per mold.
Culture medium (including treatments) was changed every 24 hours. Aggregates
were treated with 100 µM αCT1, reverse control peptide, or vehicle control.
Cx43 mimetic peptides and aggregate treatment: Two peptides (American
Peptide) were generated: αCT1 and a reverse sequence peptide (REV). These
peptides contain an N-terminal biotin tag followed by the 16-amino acid
antennapedia internalization vector (RQPKIWFPNRRKPWKK). Linked to the Cterminal K of the antennapedia sequence is either the C-terminal 9-amino acids of
Cx43 (RPRPDDLEI; αCT1) or the Cx43 C-terminal 9-amino acids in reverse
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(IELDDPRPR; REV; Fig. 1-6). Aggregates were treated with 100 µM αCT1 or REV
peptide in culture medium with daily medium changes.
Live imaging of aggregates: Aggregates were imaged at 24, 48, and 72 hours after
fibroblasts were seeded. An upright Leica SP5 LSCM equipped with a 20x dipping
lens (Leica HCX Apo L 20x/0.5 UVI, 506147) was submerged in the well of a 24well plate containing each micromold (each micromold contained 96 wells, each
with a single aggregate). Alternatively, an inverted Leica SP8 LSCM equipped with
a heated, humidified, and CO2–injected incubation system and a 10x lens (Leica
HC Plan Apo 10x/0.4 NA) was used to image aggregates in micromolds sitting in
MatTek plates with no loss of optical clarity. 15 aggregates were imaged live and
analyzed for various model parameters including size, cell migration, and cell
number.
Immunolabeling: Aggregates were washed in PBS, fixed for 10 minutes at room
temperature in 4% paraformaldehyde, and washed 3x in PBS. The depression at
the top of the micromold was filled with molten agarose and allowed to gel in order
to prevent aggregates from being lost from micromold wells. Micromolds were
placed in 30% sucrose (company) overnight, embedded in OCT and frozen.
Micromolds were cryosectioned at 10 µm and dried on positively charged slides
for 30 minutes prior to immunolabeling. Slides were either stored at -80°C or were
immunolabeled immediately. Sections of aggregates were blocked with 1% BSA
(Fisher Scientific), 0.1% Triton-X-100 (Fisher Scientific) in PBS. Sections were
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immunolabeled for vimentin (Millipore) (1:1000), MF20 (DSHB) (1:100), pancadherin (clone CH-19, Sigma C1821, 1:1000), or Cx43 (Sigma or Abcam).
Labeling was viewed with AlexaFluor secondary antibodies and stained with
Hoechst 33342 (Sigma; nuclear labeling), mounted, and imaged on a Leica SP5
or SP8 LSCM equipped with a Leica Plan Apo 63x/1.4 NA oil immersion objective.
Statistical analyses: All data were checked for normality by Shapiro-Wilk [236–
240]. Non-normal data were transformed to normality using Box-Cox. If data could
not be transformed to normality, non-parametric tests were used. Normal data
were examined by ANOVA. All statistical analyses were performed in Statistical
Package for the Social Sciences (SPSS).

2.3 Results
Agarose micromolds allow generation of a high number of reproducible aggregates
of uniform size that can be subjected to live imaging
To produce a 3D heterocellular model of the IBZ, multiple techniques to generate
cell aggregates were examined. HeLa cells and HeLa cells stably expressing Cx43
(HeLa-Cx43) were used initially. The parental HeLa cell line is not known to
express connexin proteins, though the HeLa-Cx43 cell line has been transduced
to stably and heterologously express Cx43 [241]. These cells are representative
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of myocytes and fibroblasts in the heart, as cardiac fibroblasts express low levels
of connexin proteins [167,242], and myocytes express Cx43 abundantly [243,244].
First, hanging drop culture was tested by mixing equal numbers of myocytes and
fibroblasts and pipetting them into holes punched in the silicone-coated lid of a 48well plate. Cells aggregated over time, and could be spun down into the wells. This
method allowed only mixed-cell aggregates to be formed, and made manipulation
of aggregates difficult (data not shown). Also, this method produced relatively small
numbers of aggregates limiting progress rate. Second, rocker culture was tested
on a heterocellular population of aggregrates. Agarose-coated chamber slides at
various rocking speeds were seeded with HeLa-Cx43 and WT HeLa cells. A
rocking speed of 0.25 Hz resulted in clumps with 10-20 cells. Increasing the
rocking speed to 0.5 Hz resulted in clumps of 4-10 cells, with a few larger
aggregates. Increasing rocking speed further to 1 Hz resulted in clumps of 15-20
cells with many larger aggregates of cells. These larger aggregates of cells
appeared to be ~150-275 µm in diameter (Fig. 2-1A), though size could not be
precisely controlled. It also appeared that these larger clumps of cells likely
aggregated from smaller clumps of similar cells, resulting in cell separation within
the aggregates that could not be accurately regulated (Fig. 2-1B). Aggregates
generated by rocker culture were fixed, washed in PBS, and dried onto slides with
a gasket, then mounted and imaged. While this method did allow cells to be imaged
at a magnification that nearly enabled discrimination of individual cells (Fig. 2-1),
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Figure 2-1. Heterocellular aggregate generation by rocker culture. A) Aggregate size
cannot be precisely controlled at 1 Hz. B) Even mixing of heterocellular populations cannot
be controlled at 1 Hz.

this proved a relatively low-throughput method. Aggregates were also not able to
be imaged live, as they could not be efficiently immobilized.
In order to create cell aggregates of more precisely controlled and consistent size,
micromolds from microtissues.com were tested (Fig. 2-2A) [245,246]. These molds
can be filled with a non-adhesive, permeable material and a cell suspension can
be seeded into the depression on the top of the mold. The cell suspension is
allowed to settle and aggregate over time. One of the objectives in developing this
model was to create a simple way to image live cells within these aggregates, as
we would be able to track their organization over time. Therefore, we wanted a
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material for the micromolds that was optically transparent. While acrylamide was
more transparent than Ultrapure agarose, tested cells frequently failed to properly
aggregate, adhering to the sides of acrylamide microwells (Fig. 2-2B). Ultrapure
agarose (Fig. 2-2C) was found to provide an optimal substrate for promoting
formation of aggregates, thus, we used this material for further development of our
model of the IBZ.
Optimization of aggregate size for the IBZ model involved testing a variety of cell
seeding densities. To do this, we used a more cardiac-relevant cell line – H9C2
cells – which are derived from embryonic rat myocardium. Aggregates of varying
cell densities were seeded into micromolds and images were obtained (Fig. 2-3).

Figure 2-2. Silicone molds can be used to generate microwells of optically
transparent, permeable materials (A). B) Cells did not aggregate efficiently in
acrylamide, and often adhered to the microwells. C) Cells in agarose micromolds
aggregated efficiently and formed aggregates of uniform size. Scale = 200 µm.
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The critical diffusion length of oxygen in tissues is around 200 µm [247], so this
placed an upper limit on the size of aggregates, such that cells were able to
exchange nutrients and waste and avoid the formation of necrotic zones at the
center of aggregates [248]. Furthermore, while we determined that generating
aggregates in a large range of sizes was possible, light scattering and lack of laser
penetrance constrained our ability to image into H9C2 cell aggregates deeper than
100 µm (Fig. 2-3). Thus, maintaining cell viability and the demands of the imaging
technologies available to us set our optimal aggregate size limit at ~100 µm.
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Figure 2-3. Aggregate size can be controlled by varying cell seeding density into
the micromolds (A). B) Imaging of larger aggregates was challenged by laser penetrance
and light scattering when using standard confocal techniques. Scale = 200 µm and 100
µm in A and B, respectively.

To generate a more cardiac-relevant model of the IBZ, we used neonatal rat
ventricular myocytes (NRVMs) and neonatal rat ventricular fibroblasts (NRVFs)
isolated from 2-day old rat pups. Aggregates were generated by two seeding

60

methods. In both methods, equal numbers of myocytes and fibroblasts were used.
First, myocytes were labeled with CellTracker Orange (CMRA) dye and mixed in
equal parts with fibroblasts that were labeled with CellTracker Green (CMFDA).
This mixed-cell population was then seeded into equilibrated agarose micromolds
and allowed to settle and aggregate (Fig. 2-4A). In the second method, myocytes
were labeled with CellTracker Orange (CMRA) dye and seeded into micromolds
to form a core of myocytes. Fibroblasts were cultured, then labeled with
CellTracker Green (CMFDA), and seeded into the micromolds on top of the already

Figure 2-4. 3D IBZ model incorporating myocytes and fibroblasts. A) Aggregates of
evenly mixed cells maintained this organization in culture. B) Layered aggregates with a
core of myocytes and a shell of fibroblasts led to changes over time in cell organization,
as fibroblasts migrated to the center of aggregates. C) Treatment of the IBZ model with
αCT1 led to increased fibroblast migration (p<0.05) over time. D) Myocytes appeared to
be more cohesive in αCT1-treated aggregates, whereas fibroblasts separated individual
myocytes in CTRL aggregates. This tendency could be measured by counting cluster
number (p<0.05; E). Scale = 50 µm.
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formed myocyte aggregates. This novel approach enabled the formation of an
external shell (mantle) of fibroblasts around a central core of myocytes (Fig. 2-4B).
Figure 2.5 shows immunolabeling for myocyte and fibroblast-specific proteins.
MF20 and vimentin signal overlapped with the CellTracker labeling based on the
Percoll separation of cells (e.g. vimentin labeling overlapped with CellTracker
Green-loaded fibroblasts and MF20 labeling overlapped with CellTracker Orangeloaded myocytes). This indicated that bona-fide myocyte and fibroblast
populations were being isolated and maintained in our aggregates.
Aggregates were imaged live on a confocal microscope 24, 48, and 72 hours after
fibroblast seeding. Aggregates of mixed cells showed no changes in patterns of
cell organization (Fig. 2-4A). Though previous studies of similar aggregates
reported that cells separated by cell type [249,250], this phenomenon did not occur
in our hands. In multi-layer aggregates of myocytes and fibroblasts, fibroblasts
migrated toward the center of the aggregates over time, pushing the myocytes
outward (Fig. 2-4B).
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Treatment with a peptide mimetic of connexin43 altered fibroblast migration and
patterns of cellular cohesion, which was not correlated with adhesion molecule
changes
Previous data from our lab shows that treatment with a peptide mimetic of Cx43
can improve cardiac function in an experimental model of MI [104]. To better
understand the mechanism by which this happens, we treated myocyte-fibroblast
aggregates in the IBZ culture model with this peptide (αCT1). Analysis of fibroblast
migration in these aggregates showed that this effect could be measured, and
occurred to a greater degree in fibroblasts treated with αCT1, as the average
distance of fibroblasts from the center of the aggregate decreased significantly
over time (Fig. 2-4C, p < 0.05).
Since cellular organization changes in the IBZ, we examined the in vitro model for
patterns of cellular cohesion. In CTRL aggregates, individual myocytes appeared
to be separated by fibroblasts (Fig. 2-4D). By contrast, in aggregates treated with
αCT1, myocytes and fibroblasts tended to remain more clustered together in
cohesive groups. To measure this, the number of myocyte clusters in each
aggregate was counted at the 72 hour time point, as this was the stage at which
changes in cell organization were stabilized. αCT1-treated aggregates had
significantly fewer clusters of myocytes, indicating that myocytes were more
clustered together in treated aggregates compared to controls (Fig. 2-4E, p < 0.05).
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Since adhesion molecules are known to influence patterns of cell sorting [39,40],
we examined levels of adhesion molecules using a pan-cadherin antibody that
cross reacts with all known members of the cadherin family (including N-, E-, and
P-cadherin) in fixed sections of the aggregates at 72 hours. Labeling for proteins
in whole mount aggregates was not feasible due to limitations of light penetrance
and working distance of objectives. In fixed sections of aggregates, no significant
differences in pan-cadherin levels were found between αCT1-treated aggregates
and controls (Fig. 2-6; p = 0.404 and p = 0.494). When we investigated these
phenomena further, it was found that these sorting effects were strongly correlated
to differences in levels of Cx43 in heterocellular interactions between treatment
and control (described and discussed in detail in Chapter 4). Though classical
adhesion molecule adhesive forces are much stronger than connexins, in the
absence of adhesion molecules, cells are known to sort based on connexin
proteins [41].

Extensive analysis of other model parameters revealed important markers
Other system parameters were measured that may indicate drug mechanism. All
of these changes were measured as a difference between 24 and 72 hours, though
none was significant by time or treatment. These include aggregate size and cell
number, which showed decreases of ~25% and ~20%, respectively (data not
shown). This slight reduction in aggregate size observed in response to αCT1 is
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likely accounted for by compaction of the cells within the aggregates. Though
fibroblasts moved toward the aggregate center (measured as cell distance from
the aggregate center) by ~30% over time and showed a significant treatment
effect, myocytes did not show this same change (data not shown). Another
parameter measured was ratio of red to green cells. This parameter was neither
significant by time, nor did it show a treatment effect (data not shown). These
results indicate that the Cx43 mimetic peptide likely did not significantly affect cell
proliferation or death rates. Since these are all parameters that can be measured
in live cell aggregates, these determinations can be made quickly from this model.
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Figure 2-5. Verification of cell type by immunolabeling. Fibroblasts (green) are loaded
with CellTracker Green dye and myocytes (red) are loaded with CellTracker Orange dye.
A) Vimentin labeling (blue) for fibroblasts overlaps with green signal. B) MF20 labeling
(blue) for myocytes overlaps with red signal. Scale = 50 µm.

Figure 2-6. Cadherin levels were not affected by treatment with αCT1.
Immunolabeling for pan-cadherin (A) and subsequent quantification (B) indicated no
treatment effect on levels of these adhesion molecules whether normalized to aggregate
size (left) or cell number (right). Scale = 50 µm.
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2.4 Discussion
Using non-adhesive, optically transparent micromolds, we have developed a
model of the IBZ that incorporates myocytes and fibroblasts – i.e., the dominant
cellular constituents of this pathogenic tissue in vivo. The micromolds used allowed
generation of up to 96 nearly identical cell aggregates. Larger formats would also
be feasible in theory, permitting more aggregates to be made through a single cell
seeding. The sizes of aggregates optimized in this model were within the diffusion
limit of oxygen in tissues, which would prevent the center of the aggregates from
becoming necrotic. Sequential seeding of myocytes and fibroblasts allowed the
formation of a two-layered aggregate, which could be imaged live over several
days to examine the changes in patterns of cell organization. Fibroblasts migrated
to the center of heterocellular aggregates over time, forming a more or less
coherent core of cells and pushing the myocytes outward. This effect occurred
regardless of treatment, though treatment with αCT1 increased the fibroblast
migration to a greater degree. Myocytes were also found to be more clustered
together in αCT1-treated aggregates than controls, suggesting a cellular cohesivepromoting effect of the peptide. Immunolabeling on fixed sections of aggregates
was performed, as whole mount immunolabeling did not enable visualization of
desired proteins due to physical limits. Similar levels of cadherin immunolabeling
were observed in both αCT1-treated aggregates and controls, so it appeared that
the cell sorting and clustering effects were likely not cadherin-based. Though a
number of other parameters were measured in this model, none of them showed
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statistically significant time or treatment effects. However, the ability to measure
these parameters may prove important in future evaluation of novel drug
compounds.
Cx43-ZO-1 interaction has been implicated in cardiac disease as reorganization of
Cx43 is frequently associated with arrhythmias in the heart. Many studies of heart
failure in animal models and humans have shown that Cx43-ZO-1 co-localization
is altered and Cx43 expression is reduced [79,83,251]. αCT1, a Cx43 mimetic
peptide that inhibits Cx43-ZO-1 interaction, increases GJ plaque size and
decreases association of Cx43 with ZO-1 at the plaque border [77]. Application of
αCT1 to cardiac injury may, therefore, beneficially alter Cx43-ZO-1 interaction and
reduce arrhythmogenesis. Indeed, it was found that when applied to a murine cryoinjury model of infarction, this peptide improved several metrics of cardiac
physiological function [104,230].
The mechanism by which altered cell organization contributes to arrhythmias in
the border zone is not fully understood, though these studies revealed that
application of this peptide can affect cell organization. These changes are in
parallel with the changes seen in the IBZ of our cryo-injury model of infarction,
where myocytes in the IBZ were more clustered together and appeared to be
separated by fewer fibroblasts in αCT1-treated hearts than in controls (Chapter 1).
Changes in cellular cohesiveness in this study were not found to be based on
cadherin effects, though it would be pertinent to further test the effect of cadherin-
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based sorting through knockdown experiments or using anti-cadherin antibodies
in the generation of these aggregates. We did find changes in Cx43 in
heterocellular interactions in treated aggregates versus controls that may account
for the cell sorting effect seen here (Chapter 4). Further investigation may reveal
a mechanism by which this peptide can therapeutically alter cell organization in the
IBZ in vivo to reduce arrhythmia incidence [234].
In the IBZ model, αCT1 increased migration of fibroblasts in the 3D aggregates.
This resembles a response previously seen in 2D scratch wound assays of
fibroblasts in our lab, in which cells treated with αCT1 showed a significant positive
dose-dependent migration response in a 24 hour assay. This effect was
reproduced in our 3D heterocellular model in the presence of myocytes.
While our purpose in this study was to generate a model of the IBZ, a similar
heterocellular model could be used to study other cardiac fibrotic diseases. For
example, instead of the focal scar that forms in the ischemic area in MI, diffuse
interstitial fibrosis develops in the pressure overloaded heart, with no drastic
change in cell organization. The mixed-cell aggregates where a 1:1 suspension of
myocytes and fibroblasts is seeded in the micromolds would more accurately
represent the cellular tissue structure of the pressure overloaded heart.
Additionally, ischemia could be simulated in either of these models by culturing
aggregates in a low-oxygen environment.
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3D in vitro models have been frequently used to study tissue processes and drug
development. Multicellular spheroids have been utilized to study tumor
microenvironment and growth since 1988 [252,253], and have been used more
recently to bridge the gap between in vitro and pre-clinical models in development
of cancer therapeutics [254]. A cardiac spheroid model has also been developed
in Mende’s lab [255]. While our work has been validated by a number of their
observations in this model, their work has focused primarily on modeling
electrophysiological properties and calcium handling in these microtissues, and
they do not report changes in heterocellular interactions.
While in vitro models cannot reproduce in vivo disease processes, this model
serves to simulate, at least in part, the changes in myocyte-fibroblast interaction
happening in 3D at the IBZ. Additionally, other factors important to the healing and
scar formation process may be added to this in vitro model at a relevant time point.
For instance, inflammatory cells are recruited to the heart after MI and, along with
the resident cells, release inflammatory molecules [153,256]. Bone marrow cells
are often recruited to the site of injury in tissues, though the extent of this effect in
the case of cardiac injury is debated [257–259]. These cell types – or even others
engineered to provide a therapy – could be added to this in vitro model for analysis.
This novel 3D in vitro model of the IBZ provides a reproducible method to study
changes in heterocellular interactions in live cells using an optically transparent,
porous micromolded material to form large numbers of aggregates. Using this
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model, we have shown a treatment effect of a Cx43 mimetic peptide on fibroblast
migration and cellular cohesion. Immunolabeling in fixed sections of these
aggregates may be used to identify proteins relevant to these and other processes.
Taken together, this model provides an efficient platform for efficacy testing and
mechanistic evaluation of therapeutic compounds for treating cardiac disease
processes.
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CHAPTER 3: αCT1 ALTERS CONDUCTION AND INTERCELLULAR
COMMUNICATION, BUT NOT BONE MARROW-DERIVED CELL
RECRUITMENT TO THE CRYO-INJURED HEART

3.1 Introduction
The changes in histoarchitecture, connexin distribution, and cell phenotypes that
occur in the IBZ after MI alter the electrophysiological properties of this tissue
substrate and contribute to generation of arrhythmias [160,233,260–262]. Previous
studies demonstrate action potential slowing through the IBZ [160,233], increased
coupling of myocytes and fibroblasts via connexin proteins [167,173], and altered
tissue architecture with increased collagen deposition [11,140]. Fibroblasts are
activated by injury in the myocardium and proliferate and migrate (or arrive from
extra-cardiac sources, like the bone marrow [162–165]) into the scar. Fibroblast
proliferation in the IBZ can separate myocytes from each other. There is a need to
understand the interplay between these structural changes in order to develop
targeted therapies.
While intercellular communication of myocardial cells is well-established, as
conduction spread through the myocardium is thought to rely on passage of ions
through GJs [263,264], the presence and function of heterocellular coupling via
connexins is not well understood. Heterocellular coupling is well established in
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vitro, as cells removed from the native myocardium increase their expression of
connexin proteins [152,155,265,266], and is increased in disease [173], as the
phenotype of cardiac fibroblasts changes in response to injury [267–269]. The
overall effect of this increased coupling in the context of other changes to the postMI environment is currently unknown. It may be that altered myocyte-fibroblast
coupling is responsible for changes in conduction in the IBZ. However, presence
of connexin immunolabeling used to probe heterocellular interactions in these
studies does not necessarily imply functional GJ channels. Previous work from our
lab has shown that treatment of cryo-injured hearts with αCT1 led to a reduced
propensity for inducible arrhythmias and lower arrhythmia severity score [104].
These changes were associated with an increased tendency for Cx43 to be
maintained at the IDs in the IBZ. Additionally, there was an increase in Cx43 that
was phosphorylated at serine 368 in the IBZ.
S368 phosphorylation is associated with a decrease in unitary conductance of the
GJ channel [58], perhaps as a protective mechanism against the spread of injury
signal in the heart [94,175,188,270]. Somewhat paradoxically, increased pS368
(i.e. decreased communication) in αCT1-treated hearts was associated with fewer
arrhythmias and lower arrhythmia severity scores in our studies [104]. This
suggests that communication is altered in the IBZ, though there is a need to better
understand the cellular and molecular mechanism for this.
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Cells recruited to the site of MI may also affect electrophysiological properties.
Since the first report in 2001 [271], bone marrow derived cells (BMCs) – a recruited
cell type – have been extensively studied for their utility in cardiac repair. Reports
in the literature suggest a range of contribution of BMCs – which can be mobilized
by injury signals and recruited to the site of injury – to healing of the injured heart
[162–165]. Clinical trials of exogenously applied BMCs post-MI suggest modest
benefit from paracrine factors [272] and exosome release [273,274] (i.e. the
presence of the cells themselves is not required). However, there is further room
for improvement of this type of therapy, as the BMCs could be used as a delivery
vehicle. For example, if sufficient numbers of cells are recruited to the scar and
IBZ, BMCs could be engineered to express increased levels of connexins (they
already express some [275]) and ion channels in order to improve
electrophysiological properties of the IBZ and scar.
To assess whether αCT1 alters conduction in the IBZ and can alter GJIC, we
studied the effect of the peptide on conduction velocity through the IBZ in cryoinjured hearts and examined direct intercellular communication in an in vitro
parachute communication assay. To determine the contribution of endogenous
recruited BMCs to the IBZ and scar, we transduced the femoral cavity of mice after
delivery of a cardiac cryo-injury to assess the efficiency with which labeled cells
were recruited to the site of injury.
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3.2 Methods
Animal care and use: All animal research was conducted under the guidance of
the Institutional Animal Care and Use Committee at Virginia Polytechnic Institute
and State University and conform to the NIH Guide for the Care and Usage of
Laboratory Animals.
Cryo-injury: CD-1 Mice (12-24 weeks old, Charles River Labs) were anesthetized
by exposure to 5% isoflurane in oxygen. The mice were placed in supine position
and the trachea intubated, under direct visualization, with a 22-gauge
angiocatheter over a blunt introducer. The mice were ventilated with 2% isoflurane
in oxygen at a tidal volume of 250 µl and 150 cycles/minute. Mice were given
buprenorphine pre-operatively (50-100 mg/kg SC). Maintaining sterile technique,
a left thoracotomy was performed at the fourth intercostal space, using a (MZ75,
Leica) dissecting scope. All muscles overlying the intercostal space were dissected
free and retracted with a home-built retractor. After opening the thorax, the
pericardial sack was opened and the left lung was reflected to allow a clear view
of the heart. The left ventricular free wall was cryo-injured by direct exposure to a
prechilled (10 sec) 3mm flat-tip circular probe of a cryo-gun for 5 seconds (CRYAC-3, Brymill). Treatments were delivered to the surface of the heart in
methylcellulose patches containing 100 µM αCT1 or reverse peptide, or water for
vehicle control. After cryo-injury, the incision was closed in layers using 6-0
Prolene sutures (Ethicon) and the skin sealed with Gluture skin glue (Abbott). Mice
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remained on the ventilator receiving oxygen until they began spontaneous
respiration. After surgery, the mice were given carprofen (2-5 mg/kg SC) for
analgesia and placed on a warming blanket until recovery from anesthesia was
complete. Mice were then returned to their cages where they received treatment
with buprenorphine every 12 hours for 48 hours and carprofen every 24 hours for
48 hours. Animals were sacrificed 1 week after surgery, hearts collected, and fresh
frozen in OCT.
Lentiviral transduction of bone marrow cells: After cryo-injury was performed, a
small incision was made in the skin over the mouse hindlimb patella. The knee
was placed in flexion and a 27 gauge needle was used to bore a hole through the
end of the femur into the bone marrow cavity. A 30 ga needle was used to inject
20 µL of lentiviral TurboGFP (Penn State Vector Core).
Langendorff perfusion: 8 weeks after cryo-injury and bone marrow transduction,
mice were anesthetized via isoflurane inhalation and cervically dislocated. The
hearts were quickly excised, the aorta cannulated, and retrogradely perfused.
Hearts were perfused with solutions (pH 7.4) described in Table 3-1 at a flow rate
of 1 to 1.5 ml/min maintaining the perfusion pressure at approximately 65 mmHg.
The temperatures of the perfusate and the bath were maintained at 37 °C.
Electrophysiology was quantified in hearts perfused with either low sodium and
high potassium, or high sodium and low potassium as described in Table 3-1 (5
CTRL and 4 αCT1-treated animals).
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Optical mapping: Hearts were optically mapped with the voltage-sensitive dye, Di4-ANEPPS, perfused at a concentration of 4 µM for approximately 5 min. Motion
was arrested with the electromechanical uncoupler, 2,3-butanedione monoxime,
or blebbistatin (BDM) at the concentrations listed in Table 3-1. Hearts were
stabilized against the front glass of the bath by applying slight pressure to the back
of the heart. The center of the anterior ventricular surface was paced with a
unipolar silver wire with a reference electrode at the back of the bath. Hearts were
stimulated at ~1V for 1 ms at a burst cycle length of 150 ms. Excitation light from
a halogen light source (MHAB-150W, Moritex Corporation) was filtered by a 510nm filter (Brightline Fluorescence Filter) before it reached the heart. The emitted
light was filtered by a 610-nm filter (610FG01-50(T257), Andover Corporation)
before it was recorded using aMiCam Ultima CMOS L-camera at a sampling rate
of 1000 frames/s. The camera captured optical signals from an area of 1 cm2 in a
100×100 pixel array with an interpixel resolution of 0.1 mm.
Activation times were assigned to the maximum rate of rise of an action potential
as previously reported [276] and conduction velocity was calculated using the
Bayly et al. algorithm [277]. In short, activation time was determined from the
maximum rate of optical action potential rise at each pixel, and a parabolic surface
was fit to activation times in order to determine a conduction velocity vector at each
pixel. Activation delay was calculated at multiple points along a line drawn through
the pacing site and the scar, normal to the IBZ.
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Primary cell isolation: Primary cardiac neonatal rat ventricular myocytes and
neonatal rat ventricular fibroblasts (NRVFs) were isolated from 2-day neonatal rats
by digestion in trypsin (Worthington), Pancreatin (Fisher), Collagenase II
(Worthington), and elastase (Fisher) in HBSS (Hyclone). Cells were separated on
a Percoll (GE Healthcare) gradient, and washed. Fibroblasts were seeded and
cultured in DMEM (Hyclone or Gibco) supplemented with FBS (Hyclone), 10U/ml
penicillin and 10µg/ml streptomycin (Hyclone), and 2mM L-alanyl-L-glutamine
(Fisher) and maintained in an incubator at 37°C, 5% CO2. Myocytes were seeded
in myocyte complete medium (M199 supplemented with 0.16% glucose (Sigma),
1x MEM vitamins (Gibco), 1x NEAA (Gibco), 1x MEM Amino acids (Gibco), 10
U/ml penicillin and 10 µg/ml streptomycin (Hyclone), 10% horse serum (Gibco),
and 5% FBS (Hyclone)).
Density gradient centrifugation: Due to their differences in densities, myocytes and
fibroblasts can be separated by density gradient centrifugation. As such, Percoll
(GE Healthcare) was used to generate a two-layer gradient in which a layer of
Percoll of 1.060 g/mL density was underlaid with a layer of Percoll of 1.080 g/mL
density. Cells from no more than 4 digested rat pup hearts were suspended in 1x
ADS solution, laid onto the top of the gradient, and centrifuged at 3000 rpm for 30
minutes with no brake. Myocytes sink to the bottom density interface and
fibroblasts remain at the top interface. Cells are then collected and washed in
complete medium for the respective cell type.
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Parachute assay: Myocyte or fibroblast acceptor cells were seeded and grown to
confluence on 2-well glass chamber slides coated with gelatin (myocytes) or polyL-lysine (fibroblasts). Donor fibroblasts were grown in 6-well plates. Donor and
acceptor cells were treated with 100 µM αCT1 or reverse control peptide or HBSS
vehicle control for 48 hours with daily media changes. At the time of parachute,
donor cells were loaded with 5 µM calcein AM (Life Technologies) and 2.5 µM
CellTracker Orange (CMRA) (Life Technologies) in OptiMEM (Gibco) for 45
minutes at 37°C. Donor fibroblasts were washed in PBS, trypsinized, and
parachuted in complete medium with 100 µM treatments. Transfer was allowed to
progress for 4 hours at 37°C and cells were mounted in OptiMEM and imaged on
an Olympus BX61VS slide scanner. Only transferring cells were counted.
Statistics: 2-way ANOVA was performed on optical mapping data. Comparisons
between treatment groups in a parachute assay was performed with a mixed
model design. After it was determined that interaction effects could be eliminated,
experiments were split by cell type for analysis. ANOVA was performed with Least
Significant Difference (LSD) for inter-group comparisons.
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3.3 Results
αCT1 reduces conduction delay at the IBZ
Cryo-injured hearts were optically mapped 8 weeks after injury with the voltage
sensitive dye Di-4-ANEPPs. Extracellular ion concentration was varied during the
mapping procedure by using perfusates of different composition (Table 3-1). In
control hearts, optical maps showed a crowding of isochrone lines at the
approximate location of the IBZ with low sodium and high potassium, but not with
high sodium and low potassium (Fig. 3-1A). αCT1-treated hearts showed relatively
uniform conduction through the IBZ and did not exhibit this conduction delay in low
sodium and high potassium (Fig. 3-1A). Conduction delay through the IBZ was
calculated at points along a line through the pacing site and normal to the IBZ. In
control hearts, a low sodium concentration and high potassium concentration
unmasked a significant delay that was not seen when mapped with a high sodium
concentration and low potassium concentration (Fig. 3-1B; p = 0.002). In hearts
treated with αCT1, neither solution altered conduction delay at the IBZ with respect
to the other (Fig 3-1B; p = 0.176). While αCT1-treated hearts and CTRL hearts
were not directly compared, it appears that αCT1 protected against non-uniform
conduction slowing in the IBZ in the presence of varying extracellular ion
concentration while controls did not.
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Table 3-1. Perfusate composition for optical mapping (in mM).
Solution 1
Solution 2
NaCl
130
118.3
NaHCO3
24
29
NaH2PO4
1.2
Total [Na+]
155.2
147.3
KCl
4
4.7
K2HPO4
1.4
+
Total [K ]
4
6.1
MgCl2
1
MgSO4
1
Glucose
5.6
10
CaCl2
1.8
3.4
BDM
15
10

Figure 3-1. αCT1 reduces conduction delay at the IBZ. A) Optical maps of cryo-injured
hearts in either high sodium and low potassium (left) or low sodium and high potassium
(right). An asterisk marks the approximate IBZ area. B) Low sodium and high potassium
solution unmasks a significant conduction delay at the IBZ in controls that is not seen in
αCT1-treated hearts.
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Figure 3-2. Parachute assay of gap junctional intercellular communication (GJIC).
A) Communication was assessed in myocyte-fibroblast interactions and fibroblastfibroblast interactions. Arrowheads show calcein (green) and CellTracker (red) parachuted
cells. White arrows show acceptor cells that have received calcein (green) from the
parachuted cells. B) αCT1 decreased communication between myocytes and fibroblasts
and in fibroblast homocellular connections compared to reverse and vehicle controls.
Scale = 250 µm.
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αCT1 decreases GJIC between homocellular and heterocellular contacts
Since we saw alterations in conduction at the IBZ with varying ion concentrations
in treated hearts versus controls, and previous data (Chapter 1) showed that
treating cryo-injured hearts with αCT1 led to changes in patterns of cellular
organization in the IBZ, we assessed GJIC in a parachute communication assay
to

examine

myocyte-fibroblast

communication

and

fibroblast-fibroblast

communication. To perform the parachute assay, an acceptor cell layer of NRVMs
was plated near confluence in glass chamber slides and allowed to form mature
GJs over several days in culture, as evidenced by synchronous beating of cells.
For 48 hours before the assay was performed, both donor and acceptor cells were
treated with 100 µM αCT1 or reverse or vehicle control with daily medium changes.
Donor cells were then loaded with the GJ-permeable dye Calcein green and the
GJ-impermeable dye CellTracker Orange (CMFDA) and parachuted at a 1:15
dilution on top of the confluent acceptor layer of NRVMs. The parachuted NRVFs
settled and adhered to the NRVMs. If functional GJs were formed between the
donor and acceptor cells, Calcein green, but not CellTracker Orange, was
transferred to the acceptor cells (Fig 3-2). As a measure of communication, the
acceptor cells to which dye was transferred were counted. All non-transferring cells
were excluded from the analysis.
Surprisingly, it appeared that αCT1 treatment of cultures led to a decrease in GJIC
in heterocellular parachute assays (Fig 3-2). This suggests that αCT1 treatment
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Previous data from the Gourdie lab showed that αCT1 treatment of hearts led to
an increase in pS368 and this effect was maintained in vivo for several hours after
application of the peptide [104]. Phosphorylation of Cx43 at serine 368 is known
to be associated with a decrease in unitary conductance of the GJ channel. So it
may be that the peptide is inducing phosphorylation of Cx43 in myocyte-fibroblast
connections and in fibroblast-fibroblast connections, leading to a decrease in GJIC.

Contribution of recruited bone marrow cells to healing after cryo-injury
In order to investigate the effect of αCT1-treatment on efficiency of recruitment of
BMCs, and subsequently examine whether there is a difference in GJ coupling in
the heart, we labeled the femoral bone marrow cavity of cryo-injured mice. Mice
were subjected to cryo-injury, then lentiviral Turbo-GFP was injected into the
femoral bone marrow cavity to label the cells. Theoretically, any transduced cell in
the bone marrow cavity that was recruited outside of the bone marrow would
express GFP in its new location. Mice were allowed to recover for 8 weeks before
the hearts were excised and examined.

84

Figure 3-3. Recruitment of bone marrow derived cells to the healing infarct. A&B)
Little evidence of GFP-positive cells were seen in the scar area. C) GFP-positive cells
were found on the apex of the heart. D) Adjacent to the IBZ, several brick-shaped weaklyGFP positive cells were found.
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For gross examination of recruited BMCs, hearts were cannulated and placed on
gravity perfusion and imaged on a confocal microscope with motion arrested by
BDM. Figure 3-3 depicts several scans taken from different hearts. While we did
find a few green cells on the epicardial surface of cryo-injured hearts (Fig. 33C&D), we could not find clear GFP signal in the IBZ of these hearts (Fig. 3-3B).
In the apex of the heart, there appeared to be several GFP positive cells, though
this area was not injured (Fig. 3-3C). Additionally, there was little evidence for
GFP-positive cells anywhere in the cryo-injury scar (Fig. 3-3A). Interestingly, we
did find some brick-shaped cells (possibly myocytes) that were weakly GFPpositive in the myocardium adjacent to the IBZ (Fig. 3-3D), though the significance
of these cells is unknown. Overall it appeared that recruitment of GFP-positive
BMCs to the site of cryo-injury was low.

3.4 Discussion
These studies describe data elucidating the cellular determinants of reduced
arrhythmogenicity in the IBZ of αCT1-treated hearts. αCT1 was shown to reduce
conduction delay in the IBZ in the context of altered extracellular ion concentration,
and decrease myocyte-fibroblast heterocellular communication and fibroblast
homocellular communication, though it appeared to have no effect on BMCs
recruited to the cryo-injury.
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αCT1 protected against conduction delay in the IBZ in varying extracellular ion
concentrations, while control hearts showed a significant delay in conduction
through the IBZ. These results indicate that αCT1 may be contributing to the
generation of a more uniform electrophysiological substrate in the IBZ. Previous
data from the cryo-injury model in our lab show altered patterns of cellular
localization in the IBZ of αCT1-treated hearts compared to controls (Chapter 1). In
the IBZ of control hearts, collagen deposition and fibroblasts separated individual
myocytes from each other, interrupting patterns of electrical coupling. In contrast,
myocytes in the IBZ of αCT1-treated hearts were more clustered together in
cohesive groups and showed less evidence of intercalated non-myocytes. αCT1
treatment also led to a higher percentage of myocytes to non-myocytes in the IBZ.
This correlates with experimental modeling data that shows that increasing
fibroblasts in the IBZ can exacerbate arrhythmia propensity, though this study did
not incorporate effects of cellular organization [260]. Similarly, a report by Miragoli
et al. found that ectopic activity in cultured strands of ventricular myocytes was
increased with increasing fibroblast concentrations [278].
Cardiac myocytes and fibroblasts have vastly different electrophysiological
properties, and alterations in coupling between these cell types could contribute to
arrhythmia generation. Fibroblasts – a non-excitable cell type – have a more
depolarized resting membrane potential compared to myocytes [21,242,279], and
higher membrane resistance [21,279,280] and capacitance [281,282]. In vitro and
in silico studies suggest that a fibroblast may act as a current sink when coupled
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to a myocyte [21,283], potentially giving rise to arrhythmias [284]. Studies in the
sheep heart have shown an increase in structural coupling by connexins in
heterocellular interactions in the IBZ [173], suggesting the possibility of increased
myocyte-fibroblast functional coupling in the IBZ, though the only functional in vivo
studies on heterocellular coupling were done in the sinoatrial node of healthy rabbit
heart [285]. Previous studies from our lab on the αCT1 peptide suggested an
increase in GJIC and a decrease in hemichannel-mediated communication [57].
By contrast, in our dye coupling studies, αCT1 reduced GJIC between myocytes
and fibroblasts, and among fibroblasts. Our previous data on studies of the heart
demonstrate the ability for αCT1 to increase pS368 [104,105], which decreases
communication. While this result was unexpected, reduced communication in
heterocellular contacts (which are rare in healthy myocardium [117,122]) may be
accountable for more uniform conduction in the IBZ. For example, reduced
electrotonic coupling between myocytes and fibroblasts (in which fibroblasts could
act as a current sink) would lead to more normal electrophysiological properties of
the IBZ. Interestingly, we found a large increase in the amount of Cx43 in
heterocellular interactions between myocytes and fibroblasts in our in vitro model,
though, in light of the dye coupling data presented here, it would suggest a
mechanical role for Cx43 in those interactions (see Chapter 4).
Injection of lentiviral Turbo-GFP into the femoral cavity of cryo-injured mouse
yielded few GFP-positive cells on the surface of the heart 8 weeks after injury.
BMCs are thought to be mobilized by injury signals, though they need to
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subsequently home to and engraft in the injured tissue [162–165]. This process is
not always efficient, though strategies using heterospecific homing antibodies are
being developed to improve this, and have been shown to increase engraftment of
intravascularly injected cells in the heart [286]. These antibodies are engineered
to be specific for the antigens of two cell types. In this case, they first bind to the
target cardiac cells, and then to specific antigens on the injected cells. This
strategy holds promise with both administered cell types, as well as those recruited
to the site of injury.
It is also possible that lentiviral injection into the bone marrow cavity of cryo-injured
mice did not efficiently label cells in that compartment. The percentage of BMCs
that are recruited to injured tissue is low, and this would be further challenged by
a low labeling efficiency in the bone marrow cavity. While some reports suggest
the ability of BMCs to differentiate into a myocyte-like phenotype [271], this seems
to be a rare event, if possible at all [287,288]. It is more likely that these GFPpositive brick shaped cells arose as a cell-fusion event [289]. Overall, our attempt
to study the contribution of BMCs to the cardiac cryo-injury did not yield conclusive
results. Other reporter systems exist that may provide more robust methods to
study this effect. These include bone marrow chimeras in which animals are
irradiated to kill native bone marrow, followed by subsequent transplantation of
reporter bone marrow cells in the bone marrow cavity [257,290] or a transgenic
reporter model. Robust reporter models of monocytes [291] and hematopoetic
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stem cells [292] have been developed, though tracking bone marrow
mesenchymal cells is challenged by lack of a specific marker for this cell type [293].
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CHAPTER 4: αCT1 ALTERS MYOCYTE-FIBROBLAST INTERACTIONS VIA
CONNEXIN43 AND CONNEXIN43 GAP JUNCTION PLAQUE SUBDOMAIN
ORGANIZATION

4.1 Introduction
MI induces several changes in heterocellular interactions in the IBZ and scar. One
of the best known is the reorganization of Cx43 to the lateral borders of myocytes
in the IBZ, which is thought to contribute to arrhythmia generation. While the
traditional role of connexin proteins is in intercellular communication, there are
several studies suggesting their importance in cell adhesion [36–38]. Cadherins
are known to be responsible for cell sorting as per the differential adhesion
hypothesis [39] and subsequent substantiating research [40]. Even though
cadherin adhesion forces are stronger than that of connexins, connexin-based cell
sorting effects have also been demonstrated, and these effects seem to have a
similar influence as cadherin-based effects [41]. Work from Chapter 2 suggests
that this could be the case in our models with αCT1, as altered patterns of cell
organization were seen in aggregates with no detectable treatment-induced
differences in cadherin levels.
In EM and immunolabeling studies of the heart, Cx43 can be found in interactions
between myocytes and fibroblasts [117,122]. An immunolabeling study in the
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rabbit ventricle indicated that as much as 3.2% of Cx43 was localized to the
interface of these heterocellular interactions [117], and that this percentage
increased in the IBZ after MI in the sheep [173]. Though one study in canine
infarction found a heterogeneous decrease in Cx43 in the border zone and no
evidence of heterocellular coupling [294]. However, the ability of myocytes and
fibroblasts to couple via GJs is supported by the increased expression of connexin
proteins in activated fibroblasts, which are present in the IBZ [167,172,173]. There
is further work to be done to understand the presence and distribution of myocytefibroblast coupling via Cx43 in both healthy and diseased myocardium.
Cx43 phosphorylation at serine 368 results in a decrease in unitary conductance
of the GJ channel [58]. In the post-MI heart, Cx43 pS368 is associated with the
Cx43 that is maintained at the ID, both in our studies and those of others [104,295].
Other reports have suggested that Cx43 phosphorylation is a protective
mechanism against injury spread in the heart [94,175,188,270].
Some of the first studies from our lab examining inhibition of the Cx43-ZO-1
interaction by αCT1 peptide showed that this led to an increase in GJ plaque size
[77]. Subsequent work confirmed that Cx43-ZO-1 interaction regulated GJ size by
controlling the rate at which hemichannels waiting in the perinexus flowed into the
GJ plaque [57]. Hemichannels are known to be added to the GJ at the periphery
of the plaque [26,52,56], and progressive phosphorylation seems to be associated
with their incorporation into the plaque [90]. However, some reports suggest the
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possibility that Cx43 may be phosphorylated to some extent before it reaches the
membrane [96,97]. This may affect the GJ plaque substructure, though to date,
there are no reports on GJ plaque substructure with respect to connexin
phosphorylation. Immuno-confocal images currently provide the best detail
available on the localization of proteins within the GJ. However, the majority of
these studies display findings that suggest co-localization of proteins. Super
resolution microscopy techniques are becoming more readily available and shed
some light onto the localization of proteins in the GJ plaque at the single molecule
level [120].
The previous chapter examined the presence and function of communication in
the cryo-injured hearts. Here, we aim to understand whether and how myocytes
and fibroblasts are coupled via Cx43 GJs. To examine the presence and extent of
myocyte-fibroblast coupling via GJs and the differences in structure induced in the
Cx43 GJ plaque, we use an approach based on immuno-confocal and immunosuper resolution techniques. Importantly, for the development of a robust in vitro
IBZ model, the drug responses observed in vitro are validated against the
physiological responses seen in the disease model in vivo.
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4.2 Methods
Cell isolation and labeling: Primary cardiac neonatal rat ventricular myocytes and
neonatal rat ventricular fibroblasts (NRVFs) were isolated from 2-day neonatal rats
by digestion in trypsin (Worthington), Pancreatin (Fisher), Collagenase II
(Worthington), and elastase (Fisher) in HBSS (Hyclone). Cells were separated on
a Percoll (GE Healthcare) gradient, and washed. Fibroblasts were seeded and
cultured in DMEM (Hyclone or Gibco) supplemented with FBS (Hyclone), 10U/ml
penicillin and 10µg/ml streptomycin (Hyclone), and 2mM L-alanyl-L-glutamine
(Fisher) and maintained in an incubator at 37°C, 5% CO2. Myocytes were labeled
immediately in 2.5 µM CellTracker Orange (CMRA) (Life Technologies) in
OptiMEM (Gibco) for 30 minutes and washed in myocyte complete medium (M199
supplemented with 0.16% glucose (Sigma), 1x MEM vitamins (Gibco), 1x NEAA
(Gibco), 1x MEM Amino acids (Gibco), 10U/ml penicillin and 10µg/ml streptomycin
(Hyclone), 10% horse serum (Gibco), and 5% FBS (Hyclone)). Myocytes were
seeded at 30,000 cells per mold and allowed to aggregate for 48 hours. Before
seeding, fibroblasts were washed in PBS, labeled with 2.5 µM CellTracker Green
(CMFDA) in OptiMEM (Gibco) for 30 minutes and washed in fibroblast medium.
Fibroblasts were added at 48 hours at 30,000 cells per mold. Culture medium
(including treatments) was changed every 24 hours. Aggregates were treated with
100 µM αCT1, reverse control peptide, or vehicle control.
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Cx43 mimetic peptides: Two peptides (American Peptide) were generated: αCT1
and a reverse sequence control peptide (REV). These peptides contain an Nterminal biotin tag followed by the 16-amino acid antennapedia internalization
vector (RQPKIWFPNRRKPWKK). Linked to the C-terminal lysine (K) of the
antennapedia sequence is either the C-terminal 9-amino acids of Cx43
(RPRPDDLEI; αCT1) or the Cx43 C-terminal 9-amino acids in reverse
(IELDDPRPR; REV).
Animal care and use: All animal research was conducted under the guidance of
the Institutional Animal Care and Use Committee of Virginia Polytechnic and State
University and conforms to the NIH Guide for the Care and Usage of Laboratory
Animals.
Cryo-injury: CD-1 Mice (12-24 weeks old, Charles River Labs) were anesthetized
by exposure to 5% isoflurane in oxygen. The mice were placed in supine position
and the trachea intubated, under direct visualization, with a 22-gauge
angiocatheter over a blunt introducer. The mice were ventilated with 2% isoflurane
in oxygen at a tidal volume of 250 µl and 150 cycles/minute. Mice were given
buprenorphine pre-operatively (50-100 mg/kg SC). Maintaining sterile technique,
a left thoracotomy was performed at the fourth intercostal space, using a Leica
MZ75 dissecting scope. All muscles overlying the intercostal space were dissected
free and retracted with a home-built retractor. After opening the thorax, the
pericardial sack was opened and the left lung was reflected to allow a clear view
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of the heart. The left ventricular free wall was cryo-injured by direct exposure to a
prechilled (10 sec) 3mm flat-tip circular probe of a cryo-gun for 5 seconds (CRYAC-3, Brymill). Treatments were delivered to the surface of the heart in
methylcellulose patches containing 100 µM αCT1 or reverse peptide, or water for
vehicle control. After cryo-injury, the incision was closed in layers using 6-0
Prolene sutures (Ethicon) and the skin sealed with Gluture skin glue (Abbott). Mice
remained on the ventilator receiving oxygen until they began spontaneous
respiration. After surgery, the mice were given carprofen (2-5 mg/kg SC) for
analgesia and placed on a warming blanket until recovery from anesthesia was
complete. Mice were then returned to their cages where they received treatment
with buprenorphine every 12 hours for 48 hours and carprofen every 24 hours for
48 hours. Animals were sacrificed 1 week after surgery, hearts collected, and fresh
frozen in OCT.
Immunolabeling: At 72 hours, aggregates were fixed in 4% paraformaldehyde for
10 minutes at room temperature, washed, and embedded in OCT for frozen
sectioning. Aggregates were cut in thin sections of 5-10 µm and allowed to dry for
30 minutes. Cryo-injured hearts were cut in thin sections of 10 µm. Sections of
aggregates or hearts were blocked with 1% BSA (Fisher Scientific), 0.1% TritonX-100 (Fisher Scientific) in PBS. Cells were labeled for Cx43 (1:2000 Sigma, 1:100
Abcam, or 1:100 Chemicon), Cx43 pS368 (1:200 Cell Signaling), or 1:1000 pancadherin (Sigma). Hearts were counterstained with vimentin (Millipore) (1:1000)
and MF20 (DSHB) (1:100). Labeling was viewed with AlexaFluor secondary
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antibodies and stained with Hoechst 33342 (Sigma; nuclear labeling). For gSTED
immunolabeling, proteins were visualized with goat anti-rabbit Chromeo 505
(1:100) and anti-mouse biotin (1:200) followed by streptavidin- conjugated Horizon
V500 (1:100) secondary antibodies. For single molecule localization, cells and
tissue were fixed in 4% paraformaldehyde, reduced in 0.1 M glycine, permeabilized
in PBS with 0.2% Triton-X-100, and blocked in goat serum. Samples were labeled
for Cx43 (Chemicon) and Cx43 pS368 overnight at 4°C, washed and visualized
with AlexaFluor 647 (1:4000) and Cy3b (1:50).
Confocal, gSTED, and single molecule localization microscopy: For confocal,
immunolabeled samples were imaged on a Leica SP8 LSCM with a Plan
Apochromat 63x/1.4 NA oil immersion objective and Leica HyD hybrid detectors.
For gSTED, immunolabeled samples were imaged on a Leica SP8 LSCM
equipped with a gated stimulated emission depletion (gSTED) modules, a Plan
Apochromat 63x/1.4 NA oil immersion objective, Leica HyD hybrid detectors and
a 592-nm STED depletion laser. Fluorophores were imaged sequentially by frame.
Two-color gSTED super-resolution images were obtained sequentially as z-stacks
(with a step size of 10 nm) and processed using Huygens STED deconvolution
software (Scientific Volume Imaging, Hilversum, The Netherlands). This enabled a
maximum lateral full width at half maximum resolution of 22 nm using gSTED. For
single molecule localization, immunolabeled samples were imaged on a Bruker
Vutara 350 Single Molecule Localization system equipped with 555 nm and 647
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nm lasers, and 100x objective. Two-color images were obtained sequentially as zstacks with a step size of 10 nm and processed with Vutara software.
Confocal Cx43 quantification: Cx43 was quantified from images of Cx43 using the
Sigma and Abcam antibodies for total Cx43 and an antibody for Cx43 pS368 (Cell
Signalling). Image masks were created of the Cx43 labeling, myocytes (from
CellTracker Orange or MF20 immunolabeling), and fibroblasts (from CellTracker
Green, or vimentin immunolabeling) using ImageJ (NIH). Cx43 was quantified as
fibroblast, myocyte, or fibroblast-myocyte interface.
Statistical analyses: All data were checked for normality by Shapiro-Wilk [236–
240]. Non-normal data were transformed to normality using Box-Cox. If data could
not be transformed to normality, non-parametric tests were used. For Cx43 area
comparisons in myocytes, fibroblasts, and the zone of interaction of the two,
factorial ANOVA (2 x 3) was performed with posthoc analysis by Least Significant
Difference (LSD). Cx43 linear density was analyzed by ANOVA with posthoc
analysis by LSD. Cx43 pS368 linear density was analyzed by Mann-Whitney U.
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4.3 Results
αCT1 increases myocyte-fibroblast interactions via Cx43 in an in vitro IBZ model
As described in Chapter 2, we observed changes in cell organization in the in vitro
IBZ model that correlated with changes in cell organization in a cryo-injury model
of infarction (i.e. more cohesive groups of myocytes with αCT1 treatment
compared to controls). Since we observed no differences in levels of pan-cadherin
immunolabeling between treatments that would have suggested an effect of
classical adhesion molecules on the cell sorting behavior, we hypothesized that
changes in Cx43 – which also has adhesive properties – were responsible for
changes in myocyte cohesion. The greatest change in myocyte-fibroblast
organization was seen at 72 hours, so we looked for Cx43 at this time point. For
analysis of Cx43 in myocyte and fibroblast compartments, image masks were used
to separate the Cx43 immunolabeling signal into these compartments. The highest
Cx43 particle density of total Cx43 was found in the myocyte compartment, which
was expected, since myocytes have the greatest Cx43 expression in the heart (Fig.
4-1A&B). A zone of myocyte-fibroblast interaction showed the next greatest
particle density of total Cx43, and this was significantly lower than the myocyte
compartment (Fig. 4-1B; p < 0.001). Not surprisingly, the lowest levels of Cx43
were found in the fibroblast compartment and this was significantly lower than
either the myocyte compartment or the myocyte-fibroblast interaction zone (Fig. 41B; p < 0.001). In both the fibroblast compartment and in the myocyte-fibroblast
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compartment, αCT1 led to a significant increase in total Cx43 particle density (Fig.
4-1B; p < 0.001 and p < 0.05, respectively). When we measured linear Cx43
density, where the number of Cx43 particles was normalized to the length of
myocyte-fibroblast interaction, total Cx43 density was significantly increased in
αCT1-treated aggregates compared to controls (Fig. 4-1B; p < 0.05).
This analysis was repeated to examine the presence and extent of Cx43 pS368 in
myocyte-fibroblast interactions. The highest Cx43 particle density of Cx43 pS368
was found in the myocyte compartment, though this was not significantly greater
than in the myocyte-fibroblast compartment (Fig. 4-1C). Not surprisingly, the
lowest levels of Cx43 pS368 were found in the fibroblast compartment and this
was significantly lower than either the myocyte compartment or the myocytefibroblast interaction zone (Fig. 4-1C; p < 0.001). In both the myocyte compartment
and in the myocyte-fibroblast compartment, αCT1 led to a significant increase in
total Cx43 particle density (Fig. 4-1C; p < 0.05 and p < 0.05, respectively). There
was no difference in Cx43 pS368 levels in the fibroblast compartment between
αCT1-treated aggregates and controls. Linear density of Cx43 pS368 was
significantly increased in αCT1-treated aggregates compared to controls (Fig. 41C; p < 0.05).
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Figure 4-1. Myocyte-fibroblast interactions via Cx43 are increased in the IBZ in vitro
model. A) Cx43 (white) immunolabeling is mostly within the myocyte compartment (red
outline), though some is present in the fibroblast compartment (green outline). There
seems to be more punctate Cx43 in αCT1-treated aggregates. Cx43 was measured from
immunolabeled aggregates in the myocyte compartment, the fibroblast compartment, and
a zone of interaction between the two. B and C) Myocyte-fibroblast interactions via Cx43
and Cx43 pS368 were significantly increased in αCT1-treated aggregates compared to
controls. ***p < 0.001, **p < 0.01, *p < 0.05; Scale = 50 µm.

101

Overall, immunolabeling for Cx43 at the 72 hour time point showed that treatment
with αCT1 significantly increased the amount of Cx43 in myocyte-fibroblast
interactions compared to controls (Fig. 4-1). Interestingly, though Cx43 was
increased in myocyte-fibroblast heterocellular interactions, phosphorylation of
Cx43 at serine 368 was also increased. It is likely that there is a decrease in
communication in these heterocellular contacts, as we also saw a decrease in
heterocellular GJIC (Chapter 3). Increased clustering of myocytes was also seen
in the aggregates at 72 hours (Chapter 2), suggesting that instead of Cx43 playing
a role in intercellular communication, it may be serving an adhesive function in
heterocellular interactions in the IBZ.

αCT1 alters myocyte-fibroblast interactions via Cx43 in the cryo-IBZ
As another method to validate our in vitro IBZ model and to further examine the
changes in heterocellular interactions in the IBZ, we examined these interactions
in the cryo-injury model at 7 days. Immunolabeling of Cx43 pS368 was undertaken
on sections of cryo-injured mouse heart (Fig. 4-2). Confocal images demonstrated
an increase in fibroblast infiltration into the IBZ, leading to separation of myocyte
connections. Cx43 also appeared disordered in the IBZ compared to the regions
remote from the injury. There was a trend toward increasing myocyte-fibroblast
interactions via Cx43 in the IBZ.
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Figure 4-2. Murine cryo-injury model of infarction demonstrated lateralized Cx43 in
the IBZ. A) High-resolution tile scans of the cryo-IBZ and scar in reverse control and αCT1
peptide-treated hearts. Scar area is largely comprised of fibroblasts (blue), which appear
to separate myocytes (red) in the IBZ. Cx43 (green) appears decreased and lateralized in
the IBZ. B) Fibroblasts infiltrate normal myocyte connections in the IBZ, but not in regions
of the myocardium remote from the injury. C) There was a trend toward increased
myocyte-fibroblast interactions via Cx43 when measured in the IBZ.
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A novel gap junction plaque phosphorylation subdomain organization
Previous studies from our lab have shown that αCT1 increases Cx43 pS368 in a
PKC-dependent manner [104,105]. In order to better understand how these
changes influence the GJ plaque structure in terms of subdomain organization, we
undertook immuno-confocal and immuno-super-resolution imaging studies in
cultures of NVRMs and NRVFs and in cryo-injured mouse heart tissue. Cells and
tissues were labeled with antibodies directed against the non-phosphorylated form
of Cx43 and against Cx43 pS368. Confocal images of myocyte-fibroblast cocultures demonstrated presence of small, punctate GJs between myocytes and
fibroblasts (Fig. 4-3A). Signal from non-phosphorylated Cx43 and Cx43 pS368
appeared to mostly overlap in these images (Fig. 4-3B).
To get a more detailed picture of the structure of the GJ plaques in myocytefibroblast contacts in these co-cultures, we used gSTED microscopy. However, we
were unable to obtain images of these punctate plaques in myocyte-fibroblast
connections as the high laser power used for gSTED microscopy quickly
extinguished the fluorescent antibody under imaging parameters that allowed
capture of larger GJ plaques. This technique did allow us to obtain images of larger
myocyte-myocyte gap junctions (Fig. 4-3C&D). These images revealed a neverbefore-seen GJ subdomain organization with respect to non-phosphorylated Cx43
and Cx43 pS368 (Fig. 4-3C,D,E). Interestingly, co-cultures treated with αCT1
showed larger GJ plaques, though there did not appear to be a difference in
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subdomain organization between treated and control cultures. Figure 4-3E shows
the detail of non-phosphorylated Cx43 and Cx43 pS368 subdomain organization,
where it appears that these two forms of Cx43 are organized into a mosaic pattern
in the GJ plaque.
In order to understand the structure of myocyte-fibroblast Cx43 interactions in adult
tissue, we used gSTED microscopy to look for this same protein pair in sections of
cryo-injured adult mouse heart tissue. gSTED was not sufficiently robust to image
into these tissues, so we repeated this imaging study using a single molecule
localization technique. Again, we found it difficult to image myocyte-fibroblast
connections because of their small size. Images obtained of GJ plaques between
adjacent myocytes in the remote (uninjured) region of the myocardium (Fig. 4-3F)
displayed a similar GJ subdomain structure to that seen in cultures of neonatal
myocytes.

Figure 4-3. (Following page) A novel GJ plaque subdomain structure revealed by
super-resolution imaging. A) Myocytes and fibroblasts interact in culture via Cx43 GJs.
B) Inset of (A). It appears that the non-phosphorylated form (green) and Cx43 pS368 (red)
are co-localized when examined with standard confocal microscopy. C&D) αCT1
increased GJ size at the myocyte-myocyte interface. Cx43 (green) and Cx43 pS368 (red)
appeared to be organized into a mosaic pattern when imaged with super-resolution
techniques. E) Inset of (C) via gSTED microscopy. F) Structure of an ID in adult mouse
heart via single molecule localization technique.
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4.4 Discussion
In this chapter, we describe the presence of Cx43 in myocyte-fibroblast
interactions in our in vitro model of the IBZ and modulation of these interactions by
the Cx43 mimetic peptide αCT1. In the IBZ model, total Cx43 and Cx43 that is
phosphorylated at serine 368 were found to be significantly increased by treatment
with the αCT1 peptide in vitro. Subsequent examination of these interactions by
returning to the cryo-injury model of infarction suggested that αCT1 may alter
interactions in the IBZ to some extent in vivo as well. In light of these increased
myocyte-fibroblast interactions via Cx43, further examination of Cx43 GJs by
super-resolution microscopy techniques revealed a never-before-seen subdomain
organization of the GJ plaque where the non-phosphorylated form of Cx43 and
Cx43 pS368 organize into a mosaic pattern within the plaque.
Importantly, the work detailed in this chapter provide further validation of the in
vitro model of the IBZ and suggest that αCT1 may be an important tool for
modulating cellular interactions via Cx43. Data from previous chapters suggest
that this peptide has an overall beneficial effect on modulating arrhythmias, and
this chapter suggests that one of the cellular mechanisms involved may involve
Cx43 GJs.
Studies on the GJ plaque structure indicate that connexons waiting in the nonjunctional perinexus zone are added to the GJ from the edge of the plaque. It is
thought that Cx43 is inserted into the membrane mostly unphosphorylated and
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phosphorylation. In light of the novel GJ plaque sub-domain organization described
in this chapter, connexons may be either differentially phosphorylated by PKC at
S368 as they are inserted into the cell membrane, resulting in a mosaic pattern as
they are incorporated into the plaque, or they are differentially phosphorylated as
sub-domains within the GJ plaque. Studies on trafficking of Cx43 may provide
more insight into the GJ phosphorylation sub-domain organization.
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CHAPTER 5: IMMUNE MODULATION FOR IMPROVED SURVIVAL AND
ENGRAFTMENT OF STEM CELLS FOR SKELETAL MUSCLE
REGENERATION

5.1 Introduction
Though heart muscle and skeletal muscle are both of mesenchymal origin, skeletal
muscle has remarkable ability to regenerate after injury, while injury to the heart
typically results in a scar. While numerous populations of muscle stem cells have
been identified in the skeletal muscle, it is the satellite cell (SC) that is primarily
responsible for regeneration and muscle re-growth. SCs are normally quiescent,
contributing to homeostasis of muscle tissue [296]. When muscle is injured, SCs
are activated by various signals [297], proliferate, and fuse to generate mature
myofibers [298] that replace lost or damaged muscle. There is, however, a limit to
the regenerative capacity of muscle. In volumetric muscle loss (VML), which
typically occurs from injuries due to traumatic accidents or explosions like those
seen in the battlefield, large amounts of muscle tissue are lost or damaged and
scarring of the injured area results [299]. Chronic degenerative diseases like
muscular dystrophies also involve extensive scarring [300]. These conditions are
subject to reparative fibrosis, in which muscle does not fully regenerate and is
partially replaced by scar tissue, leading to impaired muscle function and patient
disability.
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Therapies for regeneration of lost or damaged muscle tissue include tissue
engineering approaches with both natural and synthetic scaffold materials
[301,302], using a variety of cells to either populate scaffolds or inject directly as
cell-based therapies (Fig. 5-1) [302–305]. For the purpose of this project, we have
focused on cell-based therapies, which allow the biochemical and biophysical
signals from the tissue environment to direct regeneration. Cell-based therapies
are challenged by low survival of implanted cells – typically, only 5-10% of cells
survive. This low survival rate would require an extremely large number of cells to
be injected in order to regenerate a large amount of tissue, resulting in high cost
of these therapies.
One factor influencing the low survival rate of implanted cells, especially in nonautologous therapies, is the immune system attack and destruction of these cells.
Major histocompatibility complex class I (MHC-I) molecules are expressed by all
cells in the body. In healthy cells, the MHC-I molecules presented are derived from
the cell’s own proteins, so the immune system recognizes these cells as ‘self.’
When infected, the cell presents some molecules derived from the proteins of the
pathogen, which activates cytotoxic T lymphocytes against those proteins and
results in killing of the infected cell [306].
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Figure 5-1. Cell sources and regenerative strategies for skeletal muscle. A variety of
cell sources are used for experimental muscle regeneration, including those derived from
the muscle itself, as well as sources outside the muscle, like bone marrow and adipose
tissue. These cells can be cultured in vitro on various substrates to form tissue engineered
muscle for transplantation. Cell may also be modified genetically and expanded in culture
for transplantation in vivo.

Bone marrow mesenchymal stem cells (BMSCs) are thought to be an ‘immuneprivileged’ cell type, making them a good candidate for increasing survival in cellbased therapies [307]. BMSCs express intermediate levels of MHC-I and lack
MHC-II entirely, enabling them to evade the immune system in allogeneic
transplantation [308]. Additionally, BMSCs are known to differentiate into multiple
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tissue types, including muscle [309–312], and have been shown to have modest
beneficial effects on healing of the heart after MI. While BMSCs can evade immune
system attack to some extent, other studies report that rejection of these cells does
occur, and it is likely because of MHC-I mismatch between the donor and recipient
[313,314].
Human cytomegalovirus (HCMV) is ubiquitously expressed in humans. It has
developed strategies to evade the immune system by downregulating MHC-I
surface molecules through production of proteins that code for the Unique Short
(US) region of the HCMV genome [315,316]. Human BMSCs genetically
engineered to express these US proteins have downregulated surface levels of
MHC-I, are protected against NK killing, and result in a 1.5 fold to 1.8 fold increase
in engraftment when implanted in fetal sheep [317]. These results suggest that
modulating MHC-I expression is a viable strategy for reducing immune system
response to implanted cells and increasing their survival.
The goal of these studies was to improve survival and engraftment of satellite cells
implanted for cell-based skeletal muscle regeneration. Here we describe
genetically engineered rat BMSCs expressing human US proteins as a proof of
principal of downregulation of MHC-I. We have also engineered a skeletal muscle
satellite cell line to express human US proteins, though further examination is
required. This method of decreasing the immune response is novel to the field of
skeletal muscle regeneration, but has been used in other fields.
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5.2 Methods
Animal care and use: All animal research was conducted under the guidance of
the Institutional Animal Care and Use Committee of Virginia Polytechnic and State
University and conforms to the NIH Guide for the Care and Usage of Laboratory
Animals.
BMSC isolation and culture: Bone marrow mesenchymal stem cells were isolated
from adult rat femurs. Femur heads were clipped off using bone reamers, and
DMEM medium was used to flush the bone marrow cavity with a syringe and 22
gauge needle. Bone marrow was collected into a 15 mL conical tube. Cells were
triturated and plated on 100 mm dishes. Non-adherent cells were removed after
24 hours. Cells were passaged no more than 5 times in DMEM (Hyclone)
supplemented with 10% FBS (Hyclone), 10 U/ml penicillin and 10 µg/ml
streptomycin (Hyclone), and 2 mM L-alanyl-L-glutamine (Fisher) and maintained
in an incubator at 37°C, 5% CO2.
H2K cell culture: H2K cells [318,319] were isolated by Terry Partridge’s lab at the
Children’s National Medical Center in Washington, DC. H2K cells were grown to a
density of 10,000/cm2 in DMEM (Hyclone) supplemented with 20 U/mL IFN-γ
(Millipore), 20% HI-FBS (Atlanta Biologicals), 2% chick embryo extract (Accurate
Chemical), 2 mM L-alanyl-L-glutamine (Fisher), 10 U/ml penicillin and 10 µg/ml
streptomycin (Hyclone) and maintained in an incubator at 33°C, 10% CO2.
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PT67 cell culture: PT67 cells transfected with constructs for HCMV Unique Short
(US) proteins US2, US3, US6, US11, and an empty vector were a gift from the lab
of Dr. Graça Almeida-Porada at the Wake Forest Institute for Regenerative
Medicine. Briefly, US2, US3, US6, and US11 DNA sequences were PCR amplified
from a clinical HCMV isolate, introducing EcoRI and XhoI restriction sites for US3,
US6, and US11 and EcoRI and SalI for US2. The purified PCR products were then
ligated into the pMSCV-Neo retroviral vector backbone (Clontech, Mountain View,
CA) that had been previously digested with EcoRI and XhoI. These recombinant
plasmids were transformed into One Shot Top10 chemically competent cells (Life
Technologies), and transformed Top10 cells were selected with ampicillin (Sigma;
50 µg/mL). Positive clones were confirmed by PCR using primers for the US insert,
miniprep digestions, and sequencing. For US3, US6, and US11 cloning, digestion
was performed with EcoRI and XhoI restriction enzymes. For US2 cloning, EcoRI
and BglII restriction sites were digested, as US2 cloning generated a SalI/XhoI
hybrid restriction site. Each US recombinant plasmid and an empty plasmid were
transfected into the RetroPack™ PT67 Packaging Cell Line (Clontech) using
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s
instructions. Stable transfectants were selected for 5 days with 500 µg/mL G418
(Fisher), starting at 72 hours after the transfection. Supernatants were collected
and filtered with 0.2 µm low protein binding syringe filters (Pall Corporation, Ann
Arbor, MI). PT67 cells are cultured in DMEM (Hyclone) supplemented with 10%
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FBS (Hyclone), 10 U/ml penicillin and 10 µg/ml streptomycin (Hyclone), and 2 mM
L-alanyl-L-glutamine (Fisher) and maintained in an incubator at 37°C, 5% CO2.
BMSC transduction: Subconfluent cultures of BMSCs were transduced for 6 hours
with filtered supernatant containing either US recombinant or empty MSCVneo
retrovirus diluted in serum-free QBSF60 medium (Quality Biological, Gaithersburg,
MD) and 8 µg/mL protamine sulfate (Calbiochem, San Diego, CA). After
transduction, stable US-recombinant BMSCs were selected with 500 µg/mL G418
(Fisher) for 5 days, replacing the selection media every 2 to 3 days. Therefore,
after the antibiotic selection, all the cells were transduced and consequently
expressing NeoR and the corresponding US HCMV gene.
H2K cell transduction: Subconfluent cultures of H2K cells were transduced for 6
hours with filtered supernatant containing either US recombinant or empty
MSCVneo retrovirus diluted in serum-free QBSF60 medium (Quality Biological,
Gaithersburg, MD) and 8 µg/mL protamine sulfate (Calbiochem, San Diego, CA).
After transduction, stable US-recombinant H2K cells were selected with 500 µg/mL
G418 (Fisher) for 5 days, replacing the selection media every 2 to 3 days.
Therefore, after the antibiotic selection, all the cells were transduced and
consequently expressing NeoR and the corresponding US HCMV gene.
Transmitted light images of transduced and untransduced H2K populations were
captured on a Life Technologies EVOS FL microscope.
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Flow cytometry analysis: BMSC, BMSC-E, BMSC-US2, BMSC-US3, BMSC-US6,
and BMSC-US11, prior to confluence, were detached by cell scraping in 1x PBS,
in order to preserve extracelluluar epitopes. Cells were counted and their viability
checked using Trypan Blue reagent. 1x106 cells were incubated for 15 minutes at
room temperature with FITC-tagged mouse anti-rat RT1A (BD Pharmingen™,
Clone OX-18) or FITC-tagged mouse IgG1ϰ isotype control antibodies. Cells were
washed, fixed with 0.1% azide in PBS, centrifuged and fixed with 1%
paraformaldehyde. Forward and side scatter plots were generated and used to
exclude the few dead cells and debris from the histogram analysis plots.

5.3 Results
HCMV US proteins downregulate MHC-I on rat bone marrow MSCs
Rat bone marrow MSCs were transduced with retroviral vectors expressing US2,
US3, US6, and US11. Non-transduced BMSCs and BMSCs transduced with an
empty vector (BMSC-E) were used as controls. 48 hours after transduction,
BMSCs were selected with 500 µg/mL G418 for 5 days with media changes every
2 to 3 days. Only cells expressing neomycin resistance (NeoR), and hence, the
expression vector for the protein of interest, survived. The morphology of the
BMSCs was not changed by transduction with the US protein constructs (data not
shown).
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Expression of MHC-I was measured by flow cytometry in cells transduced with US
proteins and their controls. Scatter plots of BMSCs from the initial experiment are
shown in Figure 5-2 with isotype controls subtracted. Figure 5-2B summarizes the
percentage of MHC-I positive cells with Median Fluorescent Intensity (MFI) ratios
in Figure 5-2C. MFI ratio was obtained by dividing MHC-I’s MFI by the respective
isotype’s MFI. Transduction of BMSC with MSCVneo empty retroviral vector
resulted in a decrease in the percentage of transduced cells expressing MHC-I
from 94.75% to 76.45%. Transduction of BMSCs with US6 and US2 resulted in the
largest decrease in surface expression of MHC-I to 62.45% and 68.36%,
respectively. This represented a ~34% and a ~28% decrease, respectively. This
reduction in MHC-I expression was also reflected in the decreased MFI ratio in
US6 and US2 transduced cells (Fig. 5-2C). Transduction of BMSCs with US3 and
US11 also resulted in decreased MHC-I expression, though to a lesser extent
(74.64% and 75.04%, respectively).

H2K cells can be transduced and selected for US-protein expression
H2K cells were transduced with retroviral vectors expressing US2, US3, US6, and
US11. Non-transduced H2K cells and H2K cells transduced with an empty vector
(H2K-E) were used as controls. 48 hours after transduction, H2K cells were
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Fig 5-2
Figure 5-2. Forced expression of human US proteins in rat BMSCs reduced cell
surface presentation of MHC-I. A) Flow cytometry scatter plots showed reduced MHC-I
presentation by ~30% in US2 and US6, which is reflected in (B). C) The median
fluorescent intensity ratio reflects the alteration in MHC-I surface expression.

selected with 500 µg/mL G418 for 5 days with media changes every 2 to 3 days.
Only cells expressing neomycin resistance (NeoR), and hence, the expression
vector for the protein of interest, survived. The morphology of the H2K cells was
not changed by transduction with the US protein constructs (Fig. 5-3).
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Figure 5-3. H2K cells can be transduced with US protein viral constructs with no
change to their morphology. Cells under selection with G418 have several rounded,
dying cells that were not transduced.

5.4 Discussion
Satellite cells have the ability to regenerate lost muscle tissue, though VML and
muscular dystrophies typically result in scarring that can inhibit muscle function.
Satellite cells have been used for tissue engineering and cell-based regenerative
medicine approaches, but these therapies are challenged by low survival and
engraftment of injected cells. One of the reasons for low cell survival is attack of
the implanted cells by the immune system, in particular, MHC-I molecule mismatch
between the donor and the recipient [313,314]. Previous studies have shown that
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downregulation of MHC-I molecules through US protein expression can improve
cell survival [317].
Here, we demonstrated proof of principal of downregulation of MHC-I on rat
BMSCs, resulting in ~30% decrease in cell surface levels of MHC-I molecules.
Additionally, we transduced H2K cells with US protein constructs and selected for
cells expressing the constructs. Further work needs to be done to examine the
relative levels of MHC-I on H2K cells by flow cytometry. Additionally, studies of
survival and engraftment need to be completed. H2K cells are particularly wellsuited to studies of this type, as they are a conditionally immortal cell type
[319,320]. These cells, isolated from the H-2Kb-tsA58 immortomouse, have a
temperature sensitive immortalizing gene, where at lower temperatures the cells
are continually mitotic, and at higher temperatures the cells terminally differentiate
and fuse into myotubes [319,320].
The immortomouse system provides the highest reproducibility across animal
experiments, as cells from a single isolation can be expanded extensively in
culture, eliminating variability due to multiple isolation of primary cells. For animal
implantation models, cell death and regeneration can be measured using the Y
chromosome – which is conserved in the immortomouse system, proving a distinct
advantage over other mouse cell lines.
Cell-based therapies for MI have included both satellite cells [321,322] and bone
marrow cells [272]. Satellite cells, a muscle progenitor, were believed to be a good
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candidate for differentiation into a contractile cell phenotype that would confer
functionality to the infarcted myocardial scar [323]. In addition to their ability to
differentiate into muscle cells, these cells can be easily expanded in vitro, are
resistant to ischemia, and have a low risk of tumorigenesis [6]. Studies of this kind
have been met with only moderate success due to the inability of satellite cells to
efficiently transdifferentiate into a cardiomyocyte-like phenotype [324,325].
The studies completed and outlined here examine the development of a technique
that can modulate the immune response to cells implanted for regenerative
therapies with the goal of improving survival and engraftment of cells.
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CHAPTER 6: CONCLUSIONS

6.1 Summary
Cardiovascular disease is the leading cause of death worldwide. Myocardial
infarction – a subset of CVD – is responsible for over 150,000 deaths each year in
the United States alone [3]. Current clinical therapies for MI are focused on
prolonging life and few new drugs make it to market due to the inefficiencies in the
drug development pipeline. In order to get more efficacious drugs to patients faster
with a focus on improving cardiac function and regenerating tissue lost to the
ischemic insult, there is a need for better platforms for testing of new therapeutics.
The IBZ is frequently the site of lethal reentrant arrhythmia generation, likely
caused by the changes in cellular and molecular remodeling that occur after MI
[11,233]. Alterations in patterns of organization of myocytes and fibroblasts,
increased fibrosis, and changes in localization of Cx43 are all thought to contribute
to the generation of a pro-arrhythmic substrate, though the mechanism of each of
these is not fully understood.
The major focus of my work is the development and validation of an in vitro model
of the IBZ with the goals of generating a disease-relevant and tissue structurerelevant model that can be used for high-throughput in vitro testing of therapeutic
compounds to target the arrhythmogenic propensity of the IBZ and utilizing this
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model to gain a better understanding of heterocellular interactions in the IBZ. The
research presented in this dissertation has generated novel contributions to the
fields of drug development and mechanistic targets for cardiac regenerative
therapies.
In chapter 2 we developed a novel in vitro model of the IBZ. This model
recapitulates disease-relevant alterations in cell organization in response to the
small peptide therapeutic (αCT1) reported in previous studies of cardiac cryo-injury
from our lab [231], and suggests an adhesive role for Cx43 in this process. Of
relevance to drug discovery is the generation of a high-throughput 3D model, which
is more tissue-relevant than the 2D in vitro testing paradigms often used prior to
pre-clinical animal models. Other experimental in vitro models of cardiovascular
disease have been used to test drugs, though these platforms are not widely used,
have not been standardized, and have not been validated against disease or drug
responses [195]. To our knowledge, none of these is an image-based platform.
Our novel in vitro model advances the field of drug development by providing a
model relevant to tissue that can be validated against disease and drug responses.
Additionally, it is the first model of its kind used to examine cell interactions in real
time.
In chapter 3 we described a delay in action potential propagation through the cryoIBZ in conditions of altered extracellular ion concentrations, though acutely treating
cryo-injured hearts with αCT1 abolished this delay when measured in 8-week

123

healed hearts. A communication assay suggested that αCT1 decreased GJIC in
myocyte-fibroblast interactions and in fibroblast-fibroblast interactions. Our studies
of recruited bone marrow cells to the cardiac infarct did not yield conclusive results
and further testing is needed. Previous studies describe conduction slowing
through the IBZ, though none have directly measured the delay in action potential
propagation. Since this delay was induced by altered extracellular ion
concentrations, these data suggest the possible influence of ephaptic coupling
mechanisms in the IBZ. Studies from our lab demonstrate the presence of cardiac
myocyte ephaptic coupling [120], though modeling studies suggest that ephaptic
effects may be present in any intercellular space, indicating a possible role for
fibroblasts in ephaptic coupling in the IBZ, though this requires further
investigation.
Previous studies from our lab showed that αCT1 treatment of cryo-injured hearts
resulted in an increase in phosphorylation at serine 368 of Cx43 (pS368) [104,105],
which decreases unitary conductance of the GJ channel. Consistent with this, we
show here that elevated Cx43 pS368 level correlates with reduction of intercellular
communication between cultured myocytes and cardiac fibroblasts. Our studies
also suggest that increased Cx43 pS368 corresponds to increased uniformity of
action potential propagation through the IBZ [104]. This property may relate to the
decreases in arrhythmic propensity observed in cryo-injured hearts [326]. This
being said, the mechanism by which αCT1 improves the physiological metrics of
injured hearts requires further investigation.
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In chapter 4 we investigated how Cx43 heterocellular interactions changed when
treated with αCT1. Cx43 and Cx43 pS368 are increased in myocyte-fibroblast
interactions in our in vitro model. Super-resolution imaging techniques revealed a
never-before-seen Cx43 GJ plaque sub-domain organization in which nonphosphorylated Cx43 and Cx43 pS368 are arranged in a mosaic pattern. Studies
exist indicating the presence of myocyte-fibroblast coupling via Cx43 in both the
normal and diseased heart, though presence of protein does not imply function.
Cx43 pS368 is associated with decreased channel conductance. Our studies
suggest that αCT1 increases myocyte-fibroblast interactions via Cx43, though it is
possible that communication is reduced, since there is also a significant increase
in Cx43 pS368 with αCT1 treatment.
Studies on the GJ plaque structure indicate that connexons waiting in the nonjunctional perinexus zone are added to the GJ from the edge of the plaque. It is
thought that Cx43 is inserted into the membrane mostly unphosphorylated and
connexin
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increasing

phosphorylation. In light of the novel GJ plaque sub-domain organization reported
herein, the data suggests that connexons are either differentially phosphorylated
by PKC at S368 as they are inserted into the cell membrane, resulting in a mosaic
pattern as they are incorporated into the GJ plaque, or they are differentially
phosphorylated as sub-domains within the GJ plaque. Further trafficking,
interaction, and biophysical studies are required to better understand how this
phosphorylation sub-domain organization arises. An enhanced understanding of
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functional coupling in the IBZ may enable development of improved therapies to
reduce arrhythmias in post-MI patients.
In chapter 5 we explored proof-of-concept of reducing immune system recognition
of cells through decreased MHC-I molecule surface presentation in BMSCs and
H2K satellite cells for application in cell-based regeneration of skeletal muscle. We
found that expression of MHC-I surface presentation could be reduced by ~30%
on BMSCs and that H2K cells could be efficiently transduced with US proteins.
Other studies have used US protein expressing BMSCs as a cell-based
regenerative therapy and shown a 1.5- to 1.8-fold improvement in cell engraftment
using these strategies [317]. Though further work in animal models needs to be
undertaken to assess the utility of this strategy for regeneration of skeletal muscle,
these studies provided proof-of-concept. While other skeletal muscle regeneration
studies have utilized BMSCs for cell-based therapy, and BMSCs are known to
contribute to skeletal muscle regeneration, none have used the approach of
directly modulating the immune system for improved survival and engraftment of
cells. These studies have the potential to advance the field by reducing cost and
improving the effectiveness of cell-based therapies, leading to reduced scarring
and improved patient outcomes.
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6.2 Challenges and limitations
Cell source
In vitro models are limited by cell source. Our model uses neonatal rat ventricular
myocytes and fibroblasts, which are easy to isolate, but do not necessarily have
the same connexin distribution as adults heart. Post-natal cardiac development
includes the progressive formation of brick-shaped myocytes with IDs and
adhesion junctions at the short ends of the cell and lower amounts of connexin at
lateral cell borders. Additionally, there are interspecies differences in cardiac
electrophysiological properties, and these have been responsible for removal of
FDA-approved drugs from the market due to previously unseen cardiotoxic effects.
Isolated human cells provide an electrophysiologically germane model, but are
difficult to obtain and maintain in culture. Large animal models like sheep and pig
are more relevant in terms of size and physiology than are rodents, but these are
expensive models. Human iPSCs have been increasingly used to model genetic
mutations affecting cardiac function, and may be a good source for in vitro model
development as well, though these cells are challenged by their limited ability to
take on a mature cardiomyocyte phenotype.
The field of cell-based regenerative medicine has been challenged by cell source
from the beginning. Ideally, cell-based therapies would use autologous cells to
reduce the effect of the immune response, though this also requires development
of serum-free culture technologies for cell expansion. Expansion of human stem
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cells in culture is slow and requires Good Laboratory Practice (GLP) facilities,
making these therapies costly. Use of non-autologous therapies requires immune
modulation of the implanted cells or engineered tissues or requires patient
immunosupression.

Disease-relevant animal models
Our in vitro model was developed using rat cells and validated against a mouse
model of MI. While these models have been developed to closely represent human
pathologies, they do not fully recapitulate human disease processes. Development
of safe and effective pharmaceuticals would be improved by development of more
disease-relevant and tissue-relevant models.

6.3 Future directions and recommendations
The in vitro IBZ model can be expanded and altered to meet the testing need,
including examination of other cell types and different compounds. For genetic
disease-relevant models, use of iPSCs from patients carrying a cardiac genetic
mutation would allow development of therapeutics for those specific diseases.
Perfusion bioreactor systems could be generated to fit the multi-well agarose
micromolds currently used, especially if the candidate compound will be delivered
systemically when used in the clinic. For local delivery, studies using cryo-injury
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model in our lab used a methylcellulose patch to deliver αCT1, though this patch
does not adhere tightly to the surface of the heart. If a candidate compound is
targeting a specific time point in the healing process, developing a delivery system
or a controlled release system would be pertinent.
Cell organization data in the cryo-IBZ model [231], as well as the work in our in
vitro model (Chapter 2) suggested a difference in cell cohesion was evident at a
100 µM dose of αCT1. Though a dose curve was not tested in either the in vitro
aggregate model or the cryo-injury model, the results of the in vitro model reflected
those of the in vivo model, suggesting that this may be a good starting
concentration for clinical testing of this drug. Previous work from the lab suggests
that fibroblast migration in scratch-wound assays increases in a dose-dependent
manner with αCT1 treatment, encompassing a range of 1 to 180 µM [327], though
further testing will be required to determine a minimum effective dose.
Optical mapping of cryo-injured hearts showed that αCT1 altered conduction in the
IBZ and this may be a result of changes in GJIC, as αCT1 reduced GJIC in
heterocellular myocyte-fibroblast connections and in homocellular fibroblast cellcell connections. This suggests that GJIC is likely altered in the IBZ, though the
mechanism remains to be understood. Studies of functional myocyte-fibroblast
coupling in the IBZ would be pertinent to determining how αCT1 affects
heterocellular interactions in the IBZ. No functional coupling studies in the
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diseased heart have been published to date. Only one study exists in normal heart,
and it demonstrates presence of functional myocyte-fibroblast dye coupling [285].
Transfer of αCT1 to heart disease and myocardial infarction patients may initially
involve the testing described above. Additionally, this peptide has completed
Phase I and Phase II clinical trials for wound healing in chronic non-healing
diabetic foot ulcers [180] and venous leg ulcers [181], where, among other results,
this peptide was proven safe and effective on these skin wounds. The clinical
progress attained in skin would speed up the time to clinic of this peptide for MI
patients, though, efficacy dose testing would be critical before this peptide could
be FDA approved. It would also be important to consider delivery methods. We
use a patch for the cryoinjury procedure in mice, but it is rare that a patient’s chest
is opened when they present in the clinic with symptoms indicating MI. While
systemic delivery is a simple option, this must be critically evaluated for the effect
of the peptide on other tissues and organs in the body. Localized catheter delivery
may be a possibility, and could be combined with endovascular procedures aimed
at opening the coronary arteries.
Our study of bone marrow recruitment to the cardiac injury did not yield conclusive
results, but did raise a number of questions about the model. Measuring the
transduction efficiency of the injection of virus in the bone marrow cavity would
enable assessment of whether recruitment is being challenged by low transduction
efficiency or low cell homing to the cryo-injured heart. Additionally, bone marrow
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chimeras may be a more robust approach to this question, as there is no transgenic
BMSC mouse due to lack of a specific marker for these cells.
As discussed in Chapter 5, H2K satellite cell US protein transduction studies
should be assessed for MHC-I surface presentation, and, pending results, taken
into animal models of survival and engraftment, using the Y-chromosome to track
these cells post-implantation. These studies may hold promise for translation to
clinical therapies if MHC-I presentation can be sufficiently suppressed to allow
better survival and engraftment of SCs for therapies in muscle loss or dystrophic
disease.
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